<SUBMISSION>
<ACCESSION-NUMBER>0001193125-06-080877
<TYPE>DEF 14A
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20060525
<FILING-DATE>20060417
<DATE-OF-FILING-DATE-CHANGE>20060417
<EFFECTIVENESS-DATE>20060417
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>PRO PHARMACEUTICALS INC
<CIK>0001133416
<ASSIGNED-SIC>2834
<IRS-NUMBER>043562325
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>DEF 14A
<ACT>34
<FILE-NUMBER>001-31791
<FILM-NUMBER>06761375
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
<PHONE>6175590033
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>ddef14a.htm
<DESCRIPTION>DEFINITIVE NOTICE & PROXY STATEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Definitive Notice &amp; Proxy Statement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SCHEDULE 14A INFORMATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section 14(a) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;) </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Filed by the Registrant <FONT FACE="WINGDINGS">&#120;</FONT> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Filed by a Party other than the Registrant </FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT
FACE="Times New Roman" SIZE="2"> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Preliminary Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Additional Materials </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting Material Pursuant to &#167;240.14a-12 </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>PRO-PHARMACEUTICALS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Name of Registrant As Specified In Its Charter) </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NOT APPLICABLE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Name of Person(s)
Filing Proxy Statement if other than the Registrant) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate box): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">No fee required. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee computed on table below per Exchange Rules 14a-6(i)(1) and 0-11. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title of each class of securities to which transaction applies: </FONT></TD></TR></TABLE>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies: </FONT></TD></TR></TABLE>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was
determined): </FONT></TD></TR></TABLE>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction: </FONT></TD></TR></TABLE>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Total fee paid: </FONT></TD></TR></TABLE>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee paid previously with preliminary materials. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amount Previously Paid: </FONT></TD></TR></TABLE>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form, Schedule or Registration Statement No.: </FONT></TD></TR></TABLE>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filing Party: </FONT></TD></TR></TABLE>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date Filed: </FONT></TD></TR></TABLE>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>PRO-PHARMACEUTICALS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>189 WELLS AVENUE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NEWTON, MASSACHUSETTS 02459 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">April 17, 2005 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman"
SIZE="2">Dear Stockholder: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">I invite you to the 2006 Annual Meeting of Stockholders of Pro-Pharmaceuticals, Inc. The meeting will be held
at 10:00 a.m. on Thursday, May&nbsp;25, 2006, at the Sheraton Needham Hotel, 100 Cabot Street, Needham, Massachusetts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On the pages
following this letter, you will find the Notice of our 2006 Annual Meeting of Stockholders, and the Proxy Statement, which describes the matters to be considered at the Annual Meeting. We have also enclosed your proxy card and our Annual Report on
Form 10-K for the year ended December&nbsp;31, 2005. You will find voting instructions on the enclosed proxy card. If your shares are held in &#147;street name&#148; (that is, held for your account by a broker or other nominee), you will receive
instructions from the holder of record that you must follow for your shares to be voted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Annual Meeting is an excellent opportunity to
learn more about Pro-Pharmaceuticals&#146; business and operations, and we hope you will be able to attend. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Thank you for your ongoing
support and continued interest in Pro-Pharmaceuticals. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Sincerely yours,</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;D<SMALL>AVID</SMALL> P<SMALL>LATT</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">David Platt, Ph.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PRO-PHARMACEUTICALS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>189 WELLS AVENUE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NEWTON, MASSACHUSETTS 02459 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NOTICE OF 2006 ANNUAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT
FACE="Times New Roman" SIZE="2">D<SMALL>ATE</SMALL> <SMALL>AND</SMALL> T<SMALL>IME</SMALL>: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Thursday, May&nbsp;25, 2006 at 10:00 a.m.,
local time </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">P<SMALL>LACE</SMALL>: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Sheraton Needham Hotel </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">100 Cabot Street </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Needham, Massachusetts 02494 </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman"
SIZE="2">I<SMALL>TEMS</SMALL> <SMALL>OF</SMALL> B<SMALL>USINESS</SMALL>: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#183;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To consider and act upon a proposal, presented to our stockholders in accordance with American Stock Exchange rules, to approve our issuing shares of common stock underlying our 7%
Convertible Debentures and related common stock purchase warrants sold on February&nbsp;14, 2006 that equal or exceed 20% of the number of shares of our common stock outstanding as of such date </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#183;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To consider and act upon a proposal to elect eight members of the Board of Directors to one-year terms </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#183;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To consider and act on a proposal to ratify the appointment of Deloitte&nbsp;&amp; Touche LLP as our independent registered public accounting firm to audit the financial statements
for our 2006 fiscal year </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="SYMBOL" SIZE="2" COLOR="#000000">&#183;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To transact such other business as may properly come before the Annual Meeting </FONT></TD></TR></TABLE> <P
STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">R<SMALL>ECORD</SMALL> D<SMALL>ATE</SMALL>: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">You are entitled to vote if you were a stockholder of record at the close of business on April&nbsp;12, 2006. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">By Order of the Board of Directors</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;D<SMALL>AVID</SMALL> P<SMALL>LATT</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">April 17, 2006</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">David Platt, Ph.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Newton, Massachusetts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>PRO-PHARMACEUTICALS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>189 WELLS AVENUE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NEWTON, MASSACHUSETTS 02459 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>April 17, 2005 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PROXY STATEMENT
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>FOR 2006 ANNUAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>May&nbsp;25, 2006, 10 a.m. local time, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Sheraton Needham Hotel, 100 Cabot Street, Needham,
Massachusetts </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">This Proxy Statement is being provided to you by the Board of Directors of Pro-Pharmaceuticals, Inc. in connection with
our 2006 Annual Meeting of Stockholders. The Annual Meeting will be held at 10:00 a.m. on Thursday, May&nbsp;25, 2006 at the Sheraton Needham Hotel, 100 Cabot Street, Needham, Massachusetts 02494, for the purposes set forth in the accompanying
Notice of Annual Meeting. We intend to mail this Proxy Statement and the accompanying Notice of Annual Meeting on or about April 19, 2006, to all stockholders entitled to vote at the Annual Meeting. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PURPOSE OF MEETING </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">At the Annual
Meeting the stockholders will consider and act upon a proposal for (1)&nbsp;approval, which is presented to you in accordance with American Stock Exchange rules, of our issuing shares of common stock underlying our 7% Convertible Debentures and
related common stock purchase warrants sold on February&nbsp;14, 2006 that equal or exceed 20% of the number of shares of our common stock outstanding as of such date; (2)&nbsp;the election of eight directors to one-year terms; and (3)&nbsp;the
ratification of the appointment of Deloitte&nbsp;&amp; Touche LLP as our independent registered public accounting firm to audit our financial statements for our 2006 fiscal year. The Board of Directors knows of no other business to be presented for
consideration at the Annual Meeting. Each proposal is described in more detail in this Proxy Statement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>INFORMATION ABOUT PROXIES AND
VOTING </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Proxies </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We urge you to
sign the enclosed proxy card and return it promptly in the return envelope by following the instructions on the proxy card (both enclosed with these materials). Proxies will be voted as directed. Any proxy card returned without directions given will
be voted &#147;FOR&#148; each of the proposals contained in this Proxy Statement and, as to any other business that may come before the Annual Meeting, in accordance with the judgment of the person or persons named in the proxy. You may revoke your
proxy at any time before the Annual Meeting by sending a notice of revocation to Pro-Pharmaceuticals, Inc. at 189 Wells Avenue, Newton, Massachusetts 02459, Attention: Vice President, Investor Relations. You may also revoke it by submitting a more
recently dated proxy to us before the Annual Meeting, or by attending the meeting and voting in person. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Solicitation of Proxies </I></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The solicitation of proxies in the enclosed form is made on behalf of the Board of Directors. We pay all costs to solicit these proxies. Our officers,
directors and employees may solicit proxies, but will not be additionally compensated for such activities. We are also working with brokerage houses and other custodians, nominees and fiduciaries to forward solicitation materials to the beneficial
owners of shares held of record by such institutions and persons. We will reimburse their reasonable expenses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Stockholders Entitled to Vote
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Only holders of record of our common stock at the close of business on April&nbsp;12, 2006 will be entitled to notice of the Annual
Meeting and to vote at the meeting. At the close of business on March&nbsp;15, 2006, 27,315,411 </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">shares of our common stock were outstanding and entitled to vote. Each holder of record of common stock on April&nbsp;12, 2006 is entitled to one vote for
each share held on all matters to be voted on at the Annual Meeting. There is no cumulative voting for the common stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Establishing a Quorum
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Holders of at least one third of our shares of common stock issued and outstanding must be present or represented at the Annual Meeting
to have a quorum for conducting business. Shares as to which a broker indicates that it has no discretion to vote and which are not voted, known as &#147;broker non-votes,&#148; will be considered present at the Annual Meeting for purposes of
determining the presence of a quorum, but such shares have no effect on the approval of the proposals described in this Proxy Statement. Proxies marked as abstaining on any matter to be acted on by the stockholders will be treated as present at the
Annual Meeting for purposes of determining a quorum but will not be counted as votes cast on such matters. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Votes Required </I></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Directors will be elected by a plurality of the votes of the stockholders cast at the Annual Meeting. A majority of the shares of stockholders present in
person or by proxy and voted in favor is required for each of the other matters to be considered at the Annual Meeting. Neither abstentions nor broker non-votes will have any effect on the outcome of the votes on these matters. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>OWNERSHIP OF PRO-PHARMACEUTICALS, INC. COMMON STOCK </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The following table sets forth certain information regarding beneficial ownership of our common stock, as of March&nbsp;15, 2006, by (1)&nbsp;each stockholder known to us to be the beneficial owner of more than 5% of
our outstanding shares of common stock, (2)&nbsp;each of the executive officers whose names appear in the summary compensation table as well as (3)&nbsp;each current director and (4)&nbsp;our executive officers and directors as a group. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-right:0px;margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Name <SUP>(1)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Beneficially&nbsp;Owned<SUP>&nbsp;(2)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Percentage</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>of&nbsp;Class</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">David Platt, Ph.D. </FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(3)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,539,247</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">16.6</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">James C. Czirr </FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(4)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,738,668</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">17.3</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Mildred S. Christian, Ph.D. </FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(5)</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2" COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">128,708</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Dale H. Conaway, D.V.M. </FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(6)</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2" COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">39,346</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Burton C. Firtel </FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(7)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">402,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">1.5</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Steven Prelack </FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(8)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">21,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Jerald K. Rome </FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(9)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">175,344</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">David H. Smith </FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(10)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">287,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">1.0</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Maureen E. Foley </FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(11)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">800,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">2.8</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Carl L. Lueders</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP> (8)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">50,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Eliezer Zomer</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP> (8) </SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">570,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">2.0</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">All executive officers and directors as a group (10 persons)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,012,645</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">24.0</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE><HR WIDTH="10%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Less than 1%. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The address of each of the persons listed is c/o Pro-Pharmaceuticals, Inc., 189 Wells Avenue, Newton, MA 02459. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission. In computing the number of shares owned by a person and the percentage
ownership of that person, shares of common stock subject to options and warrants held by that person that are currently exercisable or exercisable within 60 days of March&nbsp;15, 2006, are deemed outstanding. Such shares, however, are not deemed
outstanding for the purposes of computing the percentage ownership of any other person. This table has been prepared based on 27,315,411 shares of common stock outstanding as of March&nbsp;15, 2006. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes 7,379 shares owned by Dr.&nbsp;Platt&#146;s wife as to which Dr.&nbsp;Platt disclaims beneficial ownership. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes 36,400 shares owned by children of Mr.&nbsp;Czirr as to which Mr.&nbsp;Czirr disclaims beneficial ownership. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes 75,854 shares issuable upon the exercise of stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes 26,500 shares issuable upon the exercise of stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes 273,000 shares issuable upon the exercise of stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Represents shares issuable upon the exercise of stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes 16,000 shares issuable upon the exercise of stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes 123,500 shares issuable upon the exercise of stock options. Also includes 100,000 shares owned by a limited liability company of which Mr.&nbsp;Smith is a member and the
manager. Mr.&nbsp;Smith disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes 795,000 shares issuable upon the exercise of stock options. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">We are not aware of any arrangements which may result in &#147;changes in control&#148; as that term is used in Item&nbsp;403(c) of Regulation S-K. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PROPOSAL NO. 1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>TO APPROVE OUR ISSUING SHARES OF COMMON STOCK UNDERLYING THE 7% CONVERTIBLE
DEBENTURES AND COMMON STOCK PURCHASE WARRANTS WE SOLD ON FEBRUARY 14, 2006 THAT EQUAL OR EXCEED 20% OF THE NUMBER OF OUTSTANDING SHARES ON SUCH DATE </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">On February&nbsp;14, 2006, we issued and sold an aggregate $10 million original principal amount of 7% Convertible Debentures due February&nbsp;14, 2008 (the &#147;Debentures&#148;) and warrants exercisable to
purchase approximately 1.5&nbsp;million shares of our common stock (the &#147;Warrants&#148;). The holders of the Debentures and Warrants contractually require us to submit to our stockholders a proposal to approve issuances of shares of our common
stock, whether on conversion or redemption of, or payable as interest on, the Debentures, or on exercise of the Warrants (all of such shares referred to as the &#147;Underlying Shares&#148;), that would exceed of 19.99% of the number of our shares
(the &#147;Issuable Maximum&#148;) that were outstanding on February&nbsp;14, 2006 (such approval to issue shares in excess of the Issuable Maximum referred to as &#147;Shareholder Approval&#148;). We have written agreements of holders of at least
40% of our outstanding shares of common stock to vote in favor of this proposal. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The basis for such holders&#146; requirement that we seek
Shareholder Approval derives from a rule of the American Stock Exchange (the exchange on which our common stock is listed for trading) that, in general, requires that shareholder approval be obtained as a prerequisite to the exchange&#146;s approval
of an application to list additional shares to be issued in connection with a transaction in which the number of shares of common stock that are or may be sold at a price less than the greater of book or market value would equal or exceed 20% or
more of the shares outstanding as of a certain date. We have submitted an additional listing application with the American Stock Exchange to list the Underlying Shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The price per share, and, accordingly, the number of Underlying Shares that we issue in connection with a conversion or redemption, or as interest on, the Debentures, or upon exercise of the Warrants, will depend on
the future prices of our common stock on the American Stock Exchange, which may fluctuate. Redemptions and interest paid in shares must be paid at a price equal to the lesser of the then conversion price or 90% of the average of the 5 lowest VWAPs
(volume weighted average price) for the 20 consecutive trading days prior to the redemption payment. Moreover, the conversion price of the Debentures and the exercise price of the Warrants are each subject to &#147;full ratchet&#148; reduction if we
issue and sell common stock or common stock equivalents at a price lower than the then market price (known as a dilutive issuance). Although the American Stock Exchange rules permit us to issue an amount of shares up to the Issuable Maximum without
Shareholder Approval, we cannot be certain at this time that the number of Underlying Shares that we ultimately issue to meet our </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">obligations under the Debentures and Warrants will not exceed the Issuable Maximum. Without Shareholder Approval, redemptions of and interest payments on the
Debentures must be paid in cash after the Issuable Maximum is reached. We desire to retain the discretion, in order to conserve cash to support our business operations, to meet our obligations under the Debentures with payments in stock rather than
cash. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>The Board of Directors recommends a vote FOR approval of the issuance of shares of common stock underlying the Debentures and
Warrants in excess of the Issuable Maximum. </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PROPOSAL NO. 2 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ELECTION OF DIRECTORS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Nominating and Corporate Governance Committee of our
Board of Directors has nominated seven members of our Board of Directors to be re-elected, and one new member (Henry J. Esber, Ph.D.) to be elected, at the Annual Meeting to serve one-year terms until the 2007 annual meeting of stockholders and
until their respective successors are elected and shall qualify. Each nominee has agreed to serve if elected. Votes that are withheld will be counted in determining the presence of a quorum, but will have no effect on the vote. Dr.&nbsp;Esber has
consented to be named in this Proxy Statement and to serve on the Board of Directors if elected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Set forth below is information regarding
the nominees, as of March&nbsp;15, 2006, including their ages, positions with Pro-Pharmaceuticals, recent employment and other directorships. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>The Board
of Directors recommends a vote FOR the election to the Board of each of the following nominees. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="45%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-left:0px;margin-right:0px;margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Age&nbsp;as&nbsp;of&nbsp;3/15/06</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-left:0px;margin-right:0px;margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">David Platt, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">52</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">President, Chief Executive Officer, and Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Mildred S. Christian, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">63</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Dale H. Conaway, D.V.M.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">51</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Henry J. Esber, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">68</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Burton C. Firtel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">66</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Steven Prelack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">48</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Jerald K. Rome</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">71</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">David H. Smith</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">66</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Platt has served as Chairman, President, Chief Executive Officer and a director since May
2001. From 1992 to 2000, he was Chairman and Chief Executive Officer of SafeScience, Inc. (now known as GlycoGenesys, Inc.; formerly Nasdaq SmallCap: GLGS), a biotechnology company then engaged in research and development of products for treating
cancer and immune system diseases. From 1991 to 1992, Dr.&nbsp;Platt was a research scientist with the Department of Internal Medicine at the University of Michigan, Ann Arbor, and from 1988 to 1990 was a research fellow at Wayne State University
and the Michigan Cancer Foundation in Detroit (re-named Barbara Ann Karmanos Cancer Institute). Previously, he was a research fellow in the Weizmann Institute of Science, Rehovot, Israel. Dr.&nbsp;Platt received a Ph.D. in chemistry from Hebrew
University in Jerusalem and earned an M.S. and a B.S. degree from Hebrew University. He also earned a Bachelor of Engineering degree from Technion in Haifa, Israel. Dr.&nbsp;Platt has published peer review articles and holds many patents, primarily
in the field of carbohydrate chemistry. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Christian has served as a director since October 2002. She is President of Argus
International, Inc., a provider of consulting services in regulatory affairs, and Chairman and Chief Executive Officer of Argus Health Products, LLC, which develops and internationally distributes preventive and maintenance health care products for
health care professionals and the over-the-counter market. Until 2002, she was Executive Director of </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">Research of Argus and Redfield Laboratories, both divisions of Charles River Laboratories. Before founding Argus Research Laboratories in 1979 and Argus
International in 1980, Dr.&nbsp;Christian spent 14 years in drug development at McNeil Laboratories, a division of Johnson&nbsp;&amp; Johnson Corporation. She has participated at all levels in the performance, evaluation and submission in over 1,800
pre-clinical studies, from protocol to final report. Dr.&nbsp;Christian is a member of 20 professional organizations, including current service as Councilor of the European Teratology Society and Secretary/Treasurer of the Academy of Toxicological
Sciences, and was past president of the Teratology Society, the American College of Toxicology, and the Academy of Toxicological Sciences. She is an honorary member of the Society of Quality Assurance and founding editor of the <I>Journal of
Toxicological Sciences</I>. She has edited or contributed to several major textbooks and is the author of over 120 papers and abstracts published in U.S. and international journals. Dr.&nbsp;Christian earned her Ph.D. from Thomas Jefferson
University in developmental anatomy and pharmacology, and her B.S. and M.S. degrees in zoology from Pennsylvania State University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Dr.&nbsp;Conaway has served as a director since May 2001. He is the Deputy Regional Director (Southern Region) and Chief Veterinary Medical Officer for the Office of Research Oversight, an office within the Veterans Health Administration
under the U.S. Department of Veterans Affairs. From 1998 to 2001, he served as Manager of the Equine Drug Testing and Animal Disease Surveillance Laboratories for the Michigan Department of Agriculture. From 1994 to 1998 he was Regulatory Affairs
Manager for the Michigan Department of Public Health Vaccine Production Division. Dr.&nbsp;Conaway received B.S. and D.V.M. degrees from Tuskegee Institute and an M.S. degree in pathology from the College of Veterinary Medicine at Michigan State
University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Esber is the principal at Esber D &amp; D Consulting. From 2001 to 2004 he served as Executive Director and then
Senior Consultant Business Development at Charles River Laboratories Discovery and Development Services. He is the co-founder of BioSignature Diagnostics, Inc. and Advanced Drug Delivery, Inc. He also serves on the Scientific Advisory Boards of
several biotechnology companies and is the author of more than 130 technical publications. Dr.&nbsp;Esber has more than 25 years of experience in the areas of oncology/tumor immunology and immunotherapy as well as strong knowledge in the field of
toxicology and regulatory affairs. Dr.&nbsp;Esber received a B.S. degree in biology from the College of William and Mary, an M.S. degree in public health and parasitology from the University of North Carolina, and a Ph.D. in immunology/microbiology
from West Virginia University Medical Center. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Firtel has served as a director since May 2001. He is President of Adco Medical
Supplies Inc, a company he founded in 1970. Adco Medical Supplies distributes disposable medical supplies to U.S. customers, mostly for hospital use. Mr.&nbsp;Firtel also serves as President of Plastic Fabricators Incorporated, a manufacturer of
plastic burial supplies sold through distributors to customers in the funeral industry, which was acquired by Adco Medical Supplies in 1992. Mr.&nbsp;Firtel received a B.S. degree in business administration from Boston University. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Prelack has served as a director since April 2003. Since 2001 he has served as Senior Vice President, Chief Financial Officer and Treasurer of
VelQuest Corporation, a provider of automated compliance management solutions for the pharmaceutical industry. In this capacity, he oversees business development, financial, administrative and other functions, and has been responsible for
VelQuest&#146;s transition from a development-stage company to an operating company. From 1996 to 2000, he was Senior Vice President, Chief Financial Officer and Treasurer of LifeMetrix, Inc., a leading provider of cancer disease management
services, as well as disease management technology, data and clinical trial product lines and related technology-based services. As co-founder of LifeMetrix, Mr.&nbsp;Prelack was responsible for all stages of its development, including initial seed
capital funding, execution of its strategic business plan, and sale of the company. Mr.&nbsp;Prelack is a Strategic Financial Adviser to Codeco Corporation, a designer and manufacturer of custom resisters and switches, and to OPCAT, Inc., which
specializes in OPM, a systems design and architecture platform. Mr.&nbsp;Prelack, a certified public accountant, received a B.B.A. degree from the University of Massachusetts (Amherst) with dual majors in finance and accounting. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Rome has served as a director since March 2004. He has been a private investor from 1996 to the
present. Previously, he founded Amberline Pharmaceutical Care Corp., a marketer of non-prescription pharmaceuticals, in 1993 and served as its President from 1993 to 1996. From 1980 to 1990, he served as Chairman, President and Chief Executive
Officer of Moore Medical Corp.(formerly AMEX: MMD), a national distributor of branded pharmaceuticals and manufacturer and distributor of generic pharmaceuticals, and was previously Executive Vice President of the H.L. Moore Drug Exchange, a
division of Parkway Distributors and predecessor of Moore Medical Corp. Mr.&nbsp;Rome received a B.S. degree in pharmaceutical sciences from the University of Connecticut. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Smith has served as a director since January 2002. Since 1996, he has been a Founder and Managing Director of venture capital funds, as follows:
Interim Advantage Fund, LLC (founded in 1996), Contra V.C., LLC (founded in 1998), Tailwind V.C., LLC (founded in 2000), and Fivex, LLC (founded in 2004). He has had significant business experience in the clinical laboratory industry. He was a
co-founder, Vice President and Director of Packard Bioscience, a large publicly-traded manufacturer of analytical instruments that sold to Perkin Elmer in 2002, and Founder and CEO of Canberra Clinical Laboratories, which was sold in 1986 to
MetPath, Inc., a subsidiary of Corning, Inc. Mr.&nbsp;Smith received a B.A. degree in political science from Hampden-Sydney College. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Executive Officers
and Other Significant Employees </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">David Platt has served as our President and Chief Executive Officer since May 2001. His biography is
set forth above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Carl Lueders has served as our Chief Financial Officer and Treasurer since February 2005. From 2003 to 2005, he served as
Chief Financial Officer of R.F. Morse&nbsp;&amp; Son, Inc., an agri-based company. From 2002 to 2003, he was Chief Executive Officer of Brine, Inc., a developer, manufacturer and marketer of sporting goods equipment. From 1979 to 2001,
Mr.&nbsp;Lueders held several finance and planning positions at Polaroid Corporation, including Vice President and Controller, Treasurer and Acting Chief Financial Officer. Mr.&nbsp;Lueders, a certified public accountant, received an M.B.A. from
Babson College and a B.A. in economics from the University of Massachusetts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Maureen Foley has served as our Chief Operating Officer since
October 2001 and, previously as our Manager of Operations. She also holds the office of Secretary. She has been involved in the start-up of several high tech companies, beginning with Organogenesis, an MIT spin-off developing living tissue for skin
graft and organ repair applications. In 1996, Ms.&nbsp;Foley joined Thermo Electron&#146;s Thermo Fibergen division, a paper waste processing developer. In 1999 she joined ArsDigita, a developer of business software and programs, and in 2000 she
joined eHealthDirect, a developer of medical records processing software. In these positions she has been responsible for the establishment and administration of business operations including human resources and benefits, accounting, finance and
payroll, marketing, product development, facilities management and operations, and project management. She is a Director and Chairman of Tax/Eze, Inc., a tax preparation and financial services company. Ms.&nbsp;Foley is a graduate of The Wyndham
School, Boston, Massachusetts, with a major in mechanical engineering. She has completed advanced management courses in project management, budget and planning, tax preparation and human resources. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Eliezer Zomer has served as our Executive Vice President of Manufacturing and Product Development since April 2005 and previously as our Vice President
of Manufacturing and Product Development. Prior to joining the company, Dr.&nbsp;Zomer had been the founder of Alicon Biological Control, where he served from November 2000 to July 2002. From December 1998 to July 2000, Dr.&nbsp;Zomer served as Vice
President of product development at SafeScience, Inc. and Vice President of Research and Development at Charm Sciences, Inc. from June 1987 to November 1998. Dr.&nbsp;Zomer received a B.Sc. degree in industrial microbiology from the University of
Tel Aviv in 1972, a Ph.D. in biochemistry from the University of Massachusetts in 1978, and undertook a post-doctoral study at the National Institute of Health. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Anatole Klyosov has served as Chief Scientist as a full time employee since January 2006 and previously
on a consulting basis. From 1996 to 2005 Dr.&nbsp;Klyosov was vice president, research and development for Kadant Composites, Inc., a subsidiary of Kadant, Inc., where he directed a laboratory performing work in biochemistry, microbiology, polymer
engineering, and other fields in the development of composite polymer-based products. From 1990 to 1998, Dr.&nbsp;Klyosov was visiting professor of biochemistry, Center for Biochemical and Biophysical Sciences, Harvard Medical School, and from 1981
to 1990 he was professor and head of the Carbohydrates Research Laboratory at the A.N. Bach Institute of Biochemistry, USSR National Academy of Sciences. Dr.&nbsp;Klyosov was elected as a member of the World Academy of Art and Sciences and is the
recipient of several distinguished awards including the USSR National Award in Science and Technology. He has published more than 200 peer-reviewed articles in scientific journals, authored books on enzymes, carbohydrates, and biotechnology, and
holds more than 20 patents. Dr.&nbsp;Klyosov has consulted for numerous organizations, including the World Bank and the United Nations Industrial Development Organization, and serves on the editorial boards of scientific journals in the field of
biochemistry and biotechnology. Dr.&nbsp;Klyosov earned his Ph.D. and D.Sc. degrees in physical chemistry, and an M.S. degree in enzyme kinetics, from Moscow State University. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">None of the directors or executive officers specified above share any familial relationship. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">To the best of our knowledge, there are no material proceedings to which any of our directors (all of whom are current nominees) or executive officers is
a party adverse to, or has a material interest adverse to, Pro-Pharmaceuticals. To the best of our knowledge, there have been no events under any bankruptcy act, no criminal proceedings and no judgments or injunctions that are material to the
evaluation of the ability or integrity of any director, executive officer, promoter or control person of Pro-Pharmaceuticals during the past five years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><I>Board of Directors Meetings and Committees of the Board </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">During the year ended December&nbsp;31, 2005, our Board of
Directors held nine meetings. During 2005, the Board had three standing committees: the Compensation Committee, the Audit Committee and the Nominating and Corporate Governance Committee. All of the directors on each committee are
&#147;independent&#148; within the meaning of American Stock Exchange listing standards. As required by the stock exchange rules, we held one meeting of the Board attended only by the independent (non-management) directors. During 2005,
Dr.&nbsp;Conaway attended fewer than 75% of the combined total number of meetings of the Board and committee(s) on which he serves. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2"><I>Compensation Committee </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Compensation Committee, whose members are Mildred Christian (chair) and David Smith, met four
times during 2005. The Committee is responsible for reviewing and recommending compensation policies and programs, as well as salary and benefit levels for our executive officers and other significant employees. Its specific responsibilities include
supervising and overseeing the administration of our incentive compensation and stock programs and, as such, the Committee is responsible for administration of grants and awards to directors, officers, employees, consultants and advisors under
Pro-Pharmaceuticals&#146; 2001 Stock Incentive Plan, and the 2003 Non-employee Director Stock Incentive Plan. Additional information about the Compensation Committee is provided below under the caption &#147;Report of the Compensation
Committee.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Audit Committee </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The Audit Committee, whose members are Steven Prelack (chair), Dale Conaway and Jerald Rome, met six times during 2005. Its chair met informally from time to time with our management and representatives of our
independent registered public accounting firm. The charter of the Audit Committee was filed as an exhibit to our proxy statement for the 2004 annual meeting, and is posted on our website at www.pro-pharmaceuticals.com. The Audit Committee is
responsible for oversight of the quality and integrity of the accounting, auditing and reporting practices of Pro-Pharmaceuticals. More specifically, it assists the Board of Directors in fulfilling its </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">oversight responsibilities relating to (i)&nbsp;the quality and integrity of our financial statements, reports and related information provided to
stockholders, regulators and others, (ii)&nbsp;our compliance with legal and regulatory requirements, (iii)&nbsp;the qualifications, independence and performance of our independent registered public accounting firm, (iv)&nbsp;the internal control
over financial reporting that management and the Board have established, and (v)&nbsp;the audit, accounting and financial reporting processes generally. The Committee is also responsible for review and approval of related-party transactions. The
Board has determined that Mr.&nbsp;Prelack is an &#147;audit committee financial expert&#148; within the meaning of SEC rules adopted pursuant to the Sarbanes-Oxley Act of 2002. Additional information about the Audit Committee is provided below
under the caption &#147;Report of the Audit Committee.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Nominating and Corporate Governance Committee </I></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Nominating and Corporate Governance Committee, whose members are Jerald Rome (chair), Dale Conaway and Mildred Christian, met two times during fiscal
2005. The Committee&#146;s charter is available on our website at www.pro-pharmaceuticals.com. The Nominating and Corporate Governance Committee is responsible for identifying individuals qualified to become members of the Board, and to recommend to
the Board candidates for election or re-election as directors, and for reviewing our governance policies in light of the corporate governance rules of the American Stock Exchange and the Securities and Exchange Commission. Under its charter, the
Nominating and Corporate Governance Committee is required to establish and recommend criteria for service as a director, including matters relating to professional skills and experience, board composition, potential conflicts of interest and manner
of consideration of individuals proposed by management or stockholders for nomination. The Committee believes candidates for the Board should have the ability to exercise objectivity and independence in making informed business decisions; extensive
knowledge, experience and judgment; the highest integrity; loyalty to the interests of Pro-Pharmaceuticals and its stockholders; a willingness to devote the extensive time necessary to fulfill a director&#146;s duties; the ability to contribute to
the diversity of perspectives present in board deliberations; and an appreciation of the role of the corporation in society. The Committee will consider candidates meeting these criteria who are suggested by directors, management, stockholders and
other advisers hired to identify and evaluate qualified candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Committee has adopted a policy for stockholders to submit
recommendations for director candidates. A stockholder desiring to make a recommendation may do so in writing by letter to the Nominating and Corporate Governance Committee stating the reasons for the recommendation and how the candidate may meet
the Committee&#146;s director selection criteria. The letter may be confidential and should be addressed to the Chairman of the Nominating and Corporate Governance Committee, c/o Vice President, Investor Relations, Pro-Pharmaceuticals, Inc., 189
Wells Avenue, Newton, Massachusetts 02459. The Committee will evaluate stockholder-recommended candidates in the same manner as candidates recommended by other persons. Further information about stockholder nominations will be provided on our
website as it becomes available. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Stockholder Communications with the Board of Directors </I></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Stockholders may send communications to the Board, the Chairman, or one or more non-management directors by using the contact information provided on our
website. Stockholders also may send communications by letter addressed to the Vice President, Investor Relations, Pro-Pharmaceuticals, Inc., 189 Wells Avenue, Newton, Massachusetts 02459, at (617)&nbsp;559-0033. All communications will be received
and reviewed by our Vice President, Investor Relations. Stockholder concerns about our accounting, internal controls, auditing matters or business practices will be reported to the Audit Committee. All other concerns will be reported to the
appropriate committee(s) of the Board. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Attendance of Board Members at the Annual Meeting </I></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We encourage, but do not require, our Board members to attend the annual meeting of stockholders. Four members of the Board attended our 2005 annual
meeting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXECUTIVE COMPENSATION </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table sets forth certain information regarding our Chief Executive Officer and each of our four most highly compensated executive officers
for the fiscal year ended December&nbsp;31, 2005 (the &#147;Named Executive Officers&#148;). For the 2005 fiscal year, our Named Executive Officers were David Platt, Carl Lueders, Maureen Foley and Eliezer Zomer </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Summary Compensation Table </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Long-Term Compensation</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Payouts</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Name and</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Principal</B></FONT></P> <P
STYLE="margin-right:0px;margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Salary</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>($)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>401K</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Company<BR>Match<BR>($)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Bonus<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Other</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Annual</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Compen-</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>sation</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>($)(1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Restricted<BR>Stock<BR>Award(s)</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>($)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Securities</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Under-</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Lying</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Options/</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>SARs (#)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>LTIP<BR>Payouts<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>All&nbsp;Other<BR>Compen-<BR>sation</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>($)</B></FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">David Platt, President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2005</FONT><br><FONT FACE="Times New Roman" SIZE="2">2004</FONT><br><FONT FACE="Times New Roman" SIZE="2">2003</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">260,000</FONT><br><FONT FACE="Times New Roman" SIZE="2">220,000</FONT><br><FONT FACE="Times New Roman" SIZE="2">180,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,200</FONT><br><FONT FACE="Times New Roman" SIZE="2">2,933</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">90,000</FONT><br><FONT FACE="Times New Roman" SIZE="2">100,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Carl Lueders, Chief Financial<BR>Officer (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">179,675</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31,500</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">150,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Maureen Foley, Chief Operating Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2005</FONT><br><FONT FACE="Times New Roman" SIZE="2">2004</FONT><br><FONT FACE="Times New Roman" SIZE="2">2003</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">185,000</FONT><br><FONT FACE="Times New Roman" SIZE="2">150,000</FONT><br><FONT FACE="Times New Roman" SIZE="2">120,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,600</FONT><br><FONT FACE="Times New Roman" SIZE="2">3,400</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31,500</FONT><br><FONT FACE="Times New Roman" SIZE="2">35,000</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">75,000</FONT><br><FONT FACE="Times New Roman" SIZE="2">650,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Eliezer Zomer, Executive Vice President of Manufacturing and Product Development (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2005</FONT><br><FONT FACE="Times New Roman" SIZE="2">2004</FONT><br><FONT FACE="Times New Roman" SIZE="2">2003</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">180,000</FONT><br><FONT FACE="Times New Roman" SIZE="2">150,000</FONT><br><FONT FACE="Times New Roman" SIZE="2">130,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,100</FONT><br><FONT FACE="Times New Roman" SIZE="2">1,675</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31,500</FONT><br><FONT FACE="Times New Roman" SIZE="2">35,000</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">75,000</FONT><br><FONT FACE="Times New Roman" SIZE="2">425,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><br><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE><HR WIDTH="10%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Other annual compensation includes health insurance and certain perquisites and other benefits received by the Named Executive Officers. Unless otherwise indicated, the total value
of other annual compensation does not exceed the lesser of $50,000 or 10 percent of the Named Executive Officer&#146;s total salary, 401K Company Match and bonus reported in this table. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Lueders became our Chief Financial Officer in February 2005. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Zomer acquired this title in April 2005. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Option Grants in
Last Fiscal Year </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table shows all grants of options to acquire shares of Pro-Pharmaceuticals common stock granted to the
Named Executive Officers listed in the Summary Compensation Table for the fiscal year ended December&nbsp;31, 2005. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Individual Grants</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-right:0px;margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Number
of<BR>Securities<BR>Underlying<BR>Options</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Granted</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>% of Total</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Options&nbsp;Granted</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>to
Pro-<BR>Pharmaceuticals<BR>Employees</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>in Fiscal Year</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Exercise</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Price<BR>($/<BR>Share)<SUP>(2)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman"
SIZE="1"><B>Potential&nbsp;Realizable&nbsp;Value&nbsp;at<BR>Assumed&nbsp;Annual&nbsp;Rates&nbsp;of<BR>Stock&nbsp;Price&nbsp;Appreciation&nbsp;for<BR>Option Term ($)</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>5%<SUP>(3)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>10%<SUP>(3)</SUP></B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Carl Lueders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">150,000</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP></SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(1)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">100</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2.82</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2/7/15</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">266,022</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">674,153</FONT></TD></TR>
</TABLE><HR WIDTH="10%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The options vest at the rate of 50,000 shares on February&nbsp;9, 2006, 2007 and 2008. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The exercise price equals the closing price of our common stock on the grant date, February&nbsp;11, 2005. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Potential realizable value assumes that the common stock appreciates at the rate shown (compounded annually) from the grant date until the option expiration date. The assumed rate
of appreciation is derived from an SEC regulation and is provided for illustrative purposes. It does not represent our estimate of the rate of price appreciation for our stock, nor the present value of the stock options. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Aggregated Option Exercises in Last Fiscal Year and Fiscal Year-End Option Values </I></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table shows aggregate exercises of options to purchase Pro-Pharmaceuticals&#146; common stock in the fiscal year ended December&nbsp;31,
2005 by the Named Executive Officers. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-right:0px;margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Shares</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Acquired</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>on</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Exercise</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(#)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Value</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Realized</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Number of
Securities<BR>Underlying&nbsp;Unexercised&nbsp;Options</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>at Fiscal Year-End</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Value&nbsp;of&nbsp;Unexercised</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>In-The-Money Options at<BR>Fiscal Year-End ($)<SUP>(1)</SUP></B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Unexercisable</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Carl Lueders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">150,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">34,500</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Maureen Foley</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">795,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">50,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28,750</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">57,500</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Eliezer Zomer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">570,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">50,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">28,750</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">57,500</FONT></TD></TR>
</TABLE><HR WIDTH="10%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The value of unexercised options is based on the difference between the exercise price and the $3.05 closing price on the American Stock Exchange of a share of our common stock on
December&nbsp;31, 2005. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Compensation of Directors </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">We compensate each of our non-employee directors with a grant of 500 non-qualified stock options for each meeting of our Board, and each meeting of a standing committee of the Board that such director attended during
a year of service under our 2003 Non-employee Directors Stock Incentive Plan. For service in 2005, we granted options on March&nbsp;9, 2006, which were immediately exercisable at $3.75 per share, to our non-employee directors as follows: Mildred
Christian&#151;6,500 options, Dale Conaway&#151;5,500 options, Burton Firtel&#151;4,000 options, Steven Prelack&#151;3,500 options, Jerald Rome 8,500 options and David Smith&#151;4,500 options. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We paid Mr.&nbsp;Prelack, a director and member of our Audit Committee, $60,000 for service in 2005 as chair of this Committee. We paid Dr.&nbsp;Conaway
and Messrs. Firtel and Prelack $2,300, $7,200 and $27,600 respectively in 2005 for serving on a special committee of the Board to provide oversight of our litigation matters, particularly as they concern our intellectual property. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Employment Contracts and Termination of Employment and Change-in-Control Arrangements </I></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Dr.&nbsp;David Platt </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We have
employment contracts with Dr.&nbsp;Platt and Mr.&nbsp;Lueders. Dr.&nbsp;Platt&#146;s employment contract, was filed as an exhibit to our Annual Report for the year ended December&nbsp;31, 2003 on Form 10-K on March&nbsp;30, 2004. The agreement,
which became effective on January&nbsp;2, 2004, provides that Dr.&nbsp;Platt shall serve as President and Chief Executive Officer at an initial base salary of $220,000 per year (effective in 2004 and increased to $260,000 for 2005), subject to
annual review, and shall receive our standard employee life, disability and health insurance benefits. Dr.&nbsp;Platt is also entitled to receive bonus compensation as follows: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">upon consummation of a transaction with a pharmaceutical company expected to result in at least $10,000,000 of equity investment or $50,000,000 of royalty revenue or other
substantial benefit as our Board may determine, a cash bonus of $200,000 and fully vested 10-year stock options exercisable at not less than the market value to purchase at least 200,000 of our shares of common stock; </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">upon approval by the Food and Drug Administration of each new investigational new drug application filed by us for commencement of human trials, a cash bonus of $100,000 and 100,000
of such stock options; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(iii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">upon approval by the FDA of each new drug application filed by us for any drug or drug delivery candidate, a cash bonus of $400,000 and 400,000 of such stock options; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(iv)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">a cash bonus upon achievement of goals specified by our Board as determined in the first quarter of each fiscal year, with 50% based on performance relative to his work as an
executive manager and/or scientist and 50% based on reference to objective criteria such as the market price of our stock or meeting budgets approved by the Board. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If Dr.&nbsp;Platt&#146;s employment terminates other than &#147;for cause&#148; or within twelve months
after a change of control of Pro-Pharmaceuticals, he is entitled to, among other things, severance payments for two years based on his salary as of termination, a cash payment ranging from $1,000,000 and $2,000,000 calculated by reference to prior
bonus payments, continuation of or comparable health plan benefits for him and his family for two years, and immediate vesting of any unvested stock options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The agreement requires Dr.&nbsp;Platt to assign inventions and other intellectual property to Pro-Pharmaceuticals which he conceives or reduces during employment and for such period as the company pays severance,
contains protective provisions concerning confidential information, non-competition and non-solicitation of employees, and provides for indemnification of Dr.&nbsp;Platt. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><I>Mr.&nbsp;Carl Lueders </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The agreement with Mr.&nbsp;Lueders, which became effective on
February&nbsp;9, 2005, provides that he shall serve as Chief Financial Officer at an initial base salary of $200,000 per year, subject to annual review, and shall receive our standard health insurance benefits. In the event the employment of
Mr.&nbsp;Lueders is terminated &#147;without cause&#148; he shall be paid a severance equal to two months&#146; base salary plus one month for each year of employment (not to exceed six months) and continuation of benefits for two months. The
employment agreement contains a customary provision for assignment of intellectual property, as well as protective provisions concerning confidential information, non-competition and non-solicitation of employees. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Compensation Committee Interlocks and Insider Participation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">The members of the Compensation Committee during 2005 were Mildred Christian and David Smith. None of these persons were an officer or employee of Pro-Pharmaceuticals during the fiscal year, formerly an officer of Pro-Pharmaceuticals, or
had any relationship otherwise requiring disclosure hereunder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Report of the Compensation Committee on Executive Compensation </I></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Compensation Committee determines the cash and other incentive compensation, if any, to be paid to our executive officers and key employees.
Compensation may include both cash (base salary and bonus) and equity-based compensation. Base salary is determined with reference to market norms. Bonus compensation (cash and/or options) is based on a number of factors such as our financial and
non-financial performance, including fund raising; operating within budget; enhancing our market value; developing drug candidates, including enhancing our product pipeline; and expanding our intellectual property portfolio. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Equity-based compensation is comprised of stock option grants. We believe that equity-based compensation is useful to align the economic interest of the
executive officers of Pro-Pharmaceuticals with the economic interests of our stockholders. The Compensation Committee reviews the outstanding unvested options of the key executives from time to time and may grant additional options to encourage the
retention of key executives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The compensation of Dr.&nbsp;David Platt, our Chief Executive Officer, is generally based on the same
policies and criteria as the other executive officers. In developing Dr.&nbsp;Platt&#146;s employment agreement, including bonus compensation in cash and stock options for milestone achievements, the Compensation Committee considered the factors
noted above. The Committee believes Dr.&nbsp;Platt&#146;s compensation, including salary, bonus and stock options, fall within the company&#146;s compensation philosophy and is consistent with industry norms for a development-stage pharmaceutical
company, and that severance contingencies are appropriate in light of the substantial contribution he has made to our science and intellectual property. We awarded Dr.&nbsp;Platt a cash bonus of $90,000 and incentive stock options for satisfactorily
achieving certain objectives in 2005 set by the Committee comprised of factors such as filing patent applications and meeting certain milestones for our Phase I and Phase II human clinical trials. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Committee approved an increase of the salary of Dr.&nbsp;Eliezer Zomer, our Executive Vice President
of Manufacturing and Product Development, from $180,000 in 2005 to $220,000 in 2006 in recognition of the expansion of his duties related, among other things, to management of our clinical trials as we prepared for and undertook Phase II.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We awarded cash bonuses of $31,500 to each of Dr.&nbsp;Zomer, Mr.&nbsp;Lueders and Ms.&nbsp;Foley in recognition of services during 2005
and incentive stock options as long-term retention incentives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Committee reviewed and approved the hiring on a full-time basis, as
well as the compensation arrangements for, Dr.&nbsp;Anatole Klyosov, our Chief Scientist. We believe the increase in our research and development activities, combined with expanded needs for management of our intellectual property, merited this
appointment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The objective of a formal compensation policy is to enable the Company to attract and retain qualified executives, and reward
executives for performance against a number of Company goals agreed upon for the long-term maximization of stockholder value. The Compensation Committee has implemented this policy against which to assess executive compensation. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">COMPENSATION COMMITTEE</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Mildred Christian, Ph.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">David Smith</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Performance Graph </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The graph below shows the cumulative total stockholder return assuming the investment of $100 beginning September&nbsp;10, 2002 (the date our common stock began trading on the Over-the-Counter Bulletin Board) through
December&nbsp;31, 2005, in each of Pro-Pharmaceuticals common stock, the AMEX Biotechnology Index (BTK) and the Nasdaq Biotechnology Index (NBI). Our common stock has been traded on the American Stock Exchange since September 2003. The other indices
may reflect the investment of dividends; however, we have not declared or paid any dividends to date. The price performance of Pro-Pharmaceuticals shown in the following graph is not indicative of future stock price performance. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g98207g55s70.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PROPOSAL NO. 3 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>RATIFICATION OF APPOINTMENT OF REGISTERED INDEPENDENT PUBLIC ACCOUNTING FIRM </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Board of Directors
has, subject to the ratification of the stockholders, appointed Deloitte&nbsp;&amp; Touche LLP, as the registered independent public accounting firm for Pro-Pharmaceuticals for the fiscal year ending December&nbsp;31, 2006. Deloitte&nbsp;&amp;
Touche has served as in this capacity since February 2002. We do not expect a representative of Deloitte&nbsp;&amp; Touche to be present at the Annual Meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><B>The Board recommends a vote &#147;FOR&#148; the ratification of the appointment of Deloitte&nbsp;&amp; Touche LLP as the registered independent public accounting firm for Pro-Pharmaceuticals for the fiscal year
ending December&nbsp;31, 2006. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Following is information concerning the fees paid to Deloitte&nbsp;&amp; Touche during our 2005 and
2004 fiscal years. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Fiscal&nbsp;Year</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Fiscal&nbsp;Year</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Audit Fees</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(1)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">225,615</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">154,500</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Audit-Related Fees</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(2)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">66,550</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">57,450</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Tax Fees</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(3)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,725</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,425</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Subtotal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">304,890</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">219,375</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">All Other Fees</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(4)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">66,800</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">304,890</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">286,175</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD></TR>
</TABLE><HR WIDTH="10%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><I>Audit Fees</I>.&nbsp;&nbsp;&nbsp;&nbsp;These are fees for professional services for the audit of our annual financial statements included in our Annual Report on Form 10-K and
review of financial statements included in our quarterly Form 10-Q filings, and services that are normally in connection with statutory and regulatory filings or engagements for such fiscal year. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><I>Audit-Related Fees</I>.&nbsp;&nbsp;&nbsp;&nbsp;These are fees for assurance and related services that are reasonably related to the performance of the audit or review of our
financial statements, including financial disclosures made in our equity finance documentation and registration statements filed with the SEC that incorporate financial statements and the auditors&#146; report thereon, and consultation with our
Audit Committee on financial accounting/reporting standards. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><I>Tax Fees</I>.&nbsp;&nbsp;&nbsp;&nbsp;These are fees for professional services with respect to tax compliance, in particular, preparation of our corporate tax returns.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><I>All Other Fees</I>.&nbsp;&nbsp;&nbsp;&nbsp;These are fees for all other products and services provided or performed which do not fall within one or more of the above categories.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Audit Committee has considered whether the provision of non-core audit services to Pro-Pharmaceuticals by
Pro-Pharmaceuticals&#146; principal auditor is compatible with maintaining independence. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Pre-Approval Policy and Procedures </I></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Audit Committee has adopted a policy and procedures which set forth the manner in which the Committee will review and approve all services to be
provided by the independent auditor before the auditor is retained to provide such services. The policy requires Audit Committee pre-approval of the terms and fees of the annual audit services engagement, as well as any changes in terms and fees
resulting from changes in audit scope or other items. The Audit Committee also pre-approves, on an annual basis, other audit services, and audit-related and tax services set forth in the policy, subject to estimated fee levels, on a project basis
and aggregate annual basis, which have been pre-approved by the Committee. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">All other services performed by the auditor that are not prohibited non-audit services under SEC or other
regulatory authority rules must be separately pre-approved by the Audit Committee. Amounts in excess of pre-approved limits for audit services, audit-related services and tax services require separate pre-approval of the Audit Committee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Chief Financial Officer reports quarterly to the Audit Committee on the status of pre-approved services, including projected fees. All of the
services reflected in the above table were approved by the Audit Committee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>REPORT OF THE AUDIT COMMITTEE </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Audit Committee is responsible for providing independent, objective oversight of Pro-Pharmaceuticals&#146; accounting functions and internal control
over financial reporting. The Audit Committee acts under a written charter first adopted and approved by the Board of Directors in 2001, as amended in 2004, which is reviewed annually. The Audit Committee is comprised of Steven Prelack, Dale Conaway
and Jerald Rome. The Board has determined that Mr.&nbsp;Prelack is an &#147;Audit Committee Financial Expert&#148; within the meaning of the rules of the Securities and Exchange Commission. Each of the members of the Audit Committee qualifies as an
&#147;independent&#148; director under applicable American Stock Exchange rules. A copy of the Audit Committee Charter was filed as Appendix C to the Proxy Statement for our 2004 Annual Meeting of Stockholders. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Audit Committee has reviewed and discussed audited financial statements for Pro-Pharmaceuticals with management. The Audit Committee also has
discussed with Deloitte&nbsp;&amp; Touche LLP the matters required to be discussed by the Statement on Auditing Standards No.&nbsp;61, <I>Communication With Audit Committees,</I> which includes, among other items, matters related to the conduct of
the annual audit of our company&#146;s financial statements. The Audit Committee has also received and reviewed the written disclosures and the letter from Deloitte&nbsp;&amp; Touche LLP required by Independence Standards Board Standard No.&nbsp;1,
concerning their independence, as required under applicable independence standards for auditors of public companies, and has discussed with Deloitte&nbsp;&amp; Touche LLP its independence from Pro-Pharmaceuticals. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Based upon the review and discussions referred to above, the Audit Committee recommended to our Board of Directors that the audited financial statements
of Pro-Pharmaceuticals for the 2005 fiscal year be included in Annual Report filed on Form 10-K for the year ended December&nbsp;31, 2005. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">AUDIT COMMITTEE</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Steven Prelack, chair</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Dale Conaway, D.V.M.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT
FACE="Times New Roman" SIZE="2">Jerald K. Rome</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>OTHER BUSINESS </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Management knows of no other matters that may be presented at the Annual Meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>DISSENTERS&#146; RIGHTS OF APPRAISAL </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">No action is proposed herein for which
the laws of the State of Nevada, the Articles of Incorporation or By-laws of Pro-Pharmaceuticals provide a right of a stockholder to dissent and obtain appraisal of or payment for such stockholder&#146;s shares. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SECTION 16(a) BENEFICIAL OWNERSHIP </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>REPORTING COMPLIANCE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Section&nbsp;16(a) of the Securities Exchange Act of 1934
requires our officers and directors, and persons who own more than ten percent of our common stock, to file reports of ownership and changes of ownership of such securities with the Securities and Exchange Commission. Based on a review of our
records, we believe that all filing requirements applicable to our officers, directors and holders of more than ten percent of our common stock were complied with during the 2005 fiscal year. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>STOCKHOLDER PROPOSALS FOR 2007 ANNUAL MEETING </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Under SEC rules, if a
stockholder wants us to include a proposal in our Proxy Statement and form of proxy for presentation at our 2007 annual meeting of stockholders, the proposal must be received by us, attention: Vice President, Investor Relations, at our principal
executive offices by December&nbsp;29, 2006. Also in accordance with SEC guidelines, if a stockholder notifies us of that stockholder&#146;s intent to present a proposal at our 2007 annual meeting of stockholders after March&nbsp;13, 2007, we may,
acting through the persons named as proxies in the proxy materials for that meeting, exercise discretionary voting authority with respect to the proposal without including information about the proposal in our proxy materials. However, in either
case, if the date of the 2007 annual meeting is changed by more than 30 days from the date of the 2006 meeting, then the deadline would be a reasonable time before we begin to print and mail our proxy materials. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>DELIVERY OF VOTING MATERIALS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">To
reduce the expenses of delivering duplicate voting materials to our stockholders who may have more than one Pro-Pharmaceuticals stock account, we are taking advantage of &#147;householding&#148; rules that permit us to deliver only one set of the
Proxy Statement and our Annual Report on Form 10-K for the 2005 fiscal year to stockholders who share an address unless otherwise requested. If you hold your shares through a broker, you may have consented to reducing the number of copies of
materials delivered to your address. If you wish to revoke a consent previously provided to your broker, you must contact the broker to do so. In any event, if you share an address with another stockholder and have received only one set of voting
materials, you may write or call us to request a separate copy of these materials at no cost to you. For future annual meetings, you may request separate voting materials, or request that we send only one set of voting materials to you if you are
receiving multiple copies, by either: (i)&nbsp;telephoning us at (617)&nbsp;559-0033; (ii)&nbsp;sending a letter to us at 189 Wells Avenue, Newton, Massachusetts 02459, Attention: Vice President, Investor Relations; or (iii)&nbsp;sending an e-mail
to us at squeglia@pro-pharmaceuticals.com. If you hold your shares through a broker, you can request a single copy of materials for future meetings by contacting the broker. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">By Order of the Board of Directors</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;D<SMALL>AVID</SMALL> P<SMALL>LATT</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">April 17, 2006</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">David Platt, Ph.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Newton, Massachusetts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:11%"><FONT FACE="Times New Roman"
SIZE="2"><B>PROXY </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>THIS PROXY IS SOLICITED ON BEHALF OF
THE BOARD OF DIRECTORS OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>PRO-PHARMACEUTICALS, INC.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:11%; text-indent:5%"><FONT FACE="Times New Roman" SIZE="3">The undersigned appoints David Platt,
Ph.D. and Maureen Foley, and each of them, as proxies, each with the power of substitution, and authorizes each of them to represent and to vote, as designated on the reverse hereof, all of the shares of common stock of Pro-Pharmaceuticals, Inc.
held of record by the undersigned at the close of business on April 12, 2006 at the 2006 Annual Meeting of Stockholders of Pro-Pharmaceuticals, Inc. to be held on May&nbsp;25, 2006 or at any adjournment thereof. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>(Continued, and to be marked, dated and signed, on the other side) </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="2">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>PRO-PHARMACEUTICALS, INC.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="3"><B><I><U>To Vote Your Proxy </U></I></B>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="3">Mark, sign and date your proxy card below, detach it and return it in the postage-paid envelope provided. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><FONT FACE="WINGDINGS">&#218;</FONT><B></B> FOLD AND DETACH HERE AND READ THE REVERSE SIDE <FONT FACE="WINGDINGS">&#218;</FONT><B></B> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:9.60em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PROXY</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px" align="left"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>THIS PROXY WILL BE VOTED AS DIRECTED, OR IF NO DIRECTION IS INDICATED, WILL BE VOTED &#147;FOR&#148; THE PROPOSALS. THIS PROXY IS BEING
SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">Please&nbsp;mark your&nbsp;votes like this</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B><FONT FACE="WINGDINGS">&#120;</FONT><B></B></B></FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">FOR</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">AGAINST</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">ABSTAIN</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="1">1. APPROVAL TO ISSUE SHARES OF COMMON STOCK UNDERLYING THE 7% CONVERTIBLE DEBENTURES AND RELATED COMMON STOCK WARRANTS EQUAL TO OR
IN EXCESS OF 20% OF THE NUMBER OF SHARES OUTSTANDING ON FEBRUARY 14, 2006</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"></FONT><FONT FACE="WINGDINGS" SIZE="5" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="5"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"></FONT><FONT FACE="WINGDINGS" SIZE="5" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="5"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"></FONT><FONT FACE="WINGDINGS" SIZE="5" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="5"></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">VOTE&nbsp;FOR&nbsp;ALL NOMINEES</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">WITHHOLD<BR>AUTHORITY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">FOR</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">AGAINST</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">ABSTAIN</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="1">2. ELECTION OF DIRECTORS</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman"
SIZE="1"><B>To withhold authority to vote for any individual nominee, strike a line through that nominee&#146;s name below:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"></FONT><FONT FACE="WINGDINGS" SIZE="5" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="5"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"></FONT><FONT FACE="WINGDINGS" SIZE="5" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="5"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="1">3.&nbsp;RATIFICATION OF APPOINTMENT OF DELOITTE &amp; TOUCHE LLP AS THE REGISTERED INDEPENDENT PUBLIC
ACCOUNTING FIRM FOR PRO-PHARMACEUTICALS FOR 2006</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"></FONT><FONT FACE="WINGDINGS" SIZE="5" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="5"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"></FONT><FONT FACE="WINGDINGS" SIZE="5" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="5"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"></FONT><FONT FACE="WINGDINGS" SIZE="5" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="5"></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1">Mildred S. Christian, Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dale&nbsp;H.&nbsp;Conaway, D.V.M.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Henry J. Esber, Ph.D</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1">Burton C.
Firtel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;David Platt,
Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Steven Prelack</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman"
SIZE="1">Jerald K. Rome&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; David H. Smith</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="1">4.&nbsp;In their
discretion, the proxies are authorized to vote on such other business as may properly come before the Meeting.</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>COMPANY ID:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="27"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PROXY NUMBER:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="27"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ACCOUNT NUMBER:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Signature:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Signature (if joint):
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</U>
Date:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</U>, 2006 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1">Please
sign exactly as name appears hereon. When shares are held by joint owners, both should sign. When signing as attorney, executor, administrator, personal representative, trustee or guardian, please give title as such. If a corporation, please sign in
full corporate name by President or other authorized officer. If a partnership, please sign in partnership name by authorized person. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g98207g55s70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98207g55s70.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0P<4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!(P```EL````&`&<`-0`U
M`',`-P`P`````0`````````````````````````!``````````````);```!
M(P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"7\````!````<````#8`
M``%0``!&X```"6,`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``V`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#ML6GIP]`,Z)DTQ946;FL]A!]ESXR'>W'_`#EJU4TNJ83422T$G3_R
M2RZ,W`<Z@,ZU=;N?2&M(K]Y=_-UNVXS7;<G_``G_`*+6E2^KT6?K1'M'=G_D
M$E)/L]'^A/X?^22^ST?Z$_A_Y)-ZE7_<H_>S_P`BEZE7_<H_>S_R*2E_L]'^
MA/X?^22^ST?Z$_A_Y)-ZE7_<H_>S_P`BEZE7_<H_>S_R*2E_L]'^A/X?^22^
MST?Z$_A_Y)-ZE7_<H_>S_P`BEZE7_<H_>S_R*2E_L]'^A/X?^22^ST?Z$_A_
MY)-OJ_[E'[V?^02+Z@6@Y1!>=K02P2[]UOM^DDI?[/1_H3^'_DDOL]'^A/X?
M^25*KJ^!E8SK\'.9>!N#'.>UE3BS6W;?Z3FO95_AGU>KZ:(R['=<VQ_4?<6M
MK&.VRK9ZCQZGM_1MMLLM9_-[W?S?OKK24S=9A!]3&4NM]6QU)=4-[6.:UUCO
MM#V%S:?YOT_TG^%_1J6334W&N<VHM(K>0?`[3_*0*<SH]0Q\?'SJF-OG[+54
MZH!PBRS]"RMNW;^BM1<I]7V6[]9)_1OTEG[I_DI*?__0]%8.O35O=B$2SUH%
MG$_I_2EW[O\`-;U:H]3T6:CZ(['P_K+&HZ?2'8Y_81J-;Z2#ZE1%>TSZGMM]
MWV7_`*:U:0/19^K3[1^Y_P"224V(L\6_<?\`R246>+?N/_DEG_:\C[9=0>E6
MFFLUBO):ZC:_>)L=L?=78UN/]%_M_P"+43U![6.+NDY(<T&&;:"29`:T/KR'
MU>]OO_G/_!$E.E%GBW[C_P"22BSQ;]Q_\DLK-ZNS#IOO=@EU5#'V&TV8S60Q
MGJ"769#7,]1WZ/W,06?;L_'/VB@TAY#_`+/BN9M-;J]KL7+S;/;=ZECG/>_I
M^ST_T?Z5_P#A$IO7=38VZW%QBS+S:6R_%J<W>PECK:OM!<_]6]>-E3[?WT)N
M/U6W/IONSFX]/I$V=,J8TR2&ASG9C_T[O1?_`(2FO'_,1FT6"6BD4L]L,I#!
M]$;/=8\_N-V,V5U^FQ-]@P_6^T?8OUD`@9'M]4`G<Y@OW^KZ>X?S>_TTE)&=
M/#0X&ZY^_;)?:_38-K0STWU[?^$_TO\`A4SNE83W,?913:^MNQC[&>HX-#A;
MM#[2]_\`.M;9_73?IZR)QO79X_HVV#3N-S:K/=_Q7]13KMJLGTZ-T1(]@(G]
M]CG;V._KI*7QL&C$I91BU544U2*ZZV!K6[CN?M:T_GN^DC19XM^X_P#DD.!_
MW&/_`$/_`"28EK02['@#4D[(_P"J24EBSQ;IY'_R2%E^I]DOU'\V_L?W3YH)
MS<,/I9Z>YV0XLJV!KP2&ON]SJRYM;=E3_?9[%++_`*+?^KQ^C?K[/W3_`"DE
M/__1[CU^G'-<S]HYGJ#*:TTP[9ZFXQCC]!_1G.]C_?Z?_"K3IM9Z+/=9]$?F
M'_TFH>GU?U9]?']'U`0WTG[O2GW5[_7V^KL_PNS_`*T@/S[,:S[,]SRY@`#F
M8>18TB![A;0ZRO\`KI*;OJL_>L_S#_Z32]5G[UG^8?\`TFJ;.HVV%H:7^YVR
M7860P`D$R[U',]GM^FI8N;DY53K:]U8KY;=BVU..F[]&RZQCGI*;%IHNK=5;
MNLKL!:]CZRYKFD0YKVNKVN:Y2]5@T#K(_J'_`-)JA^UW;6D^L-T:?8,HD3^]
M"E=U*^EI<18[:]S(9AWO)+1OW!K'G]&[\RSZ#_H)*;OJL_>L_P`P_P#I-+U6
M?O6?YA_])JMD9F1CFL6.+A:"0ZO%NL`C;[;/1LL=7NW?GH;.IVO)#39H0#NP
MLA@U(9NFTL]K9]W_`&Y]!)3=]5G[UG^8?_2:@\4/<'N-F\1#PQP<(.Z-S6?1
M_D?00<?,R<B]]#"6&N9?9BVL88.W]':^UK+-WYFQ"_:MDD'U06F"/L&4>^W1
MS=S'?V4E),6FYF(RC,S;\NX#])>*_1+C.Z=N/6ST_P!WV(OIX<`%KG`:C<QS
MS([[K&/<J[^IW,K?9%KFLVZ-PKRX[Y^A7O\`4=LV_I?;^C1+,O)KH9D%Q=78
M0`&XMSGB9]UE#;/78W_K?L24V?59^]9_F'_TFA95K#BW^Y_\V_EA_=/\A5V]
M4L>XM:;)VEVN#DM!VR2-UFUN[V^UOYZ3\R_(M.""\.N81ZAQ+A6-S-_NO=9Z
M.[^3O_G/T22G_]+U5)?*J22GZB]3)V2:B7Q]'V@3X;O4*#]HZI%OZFT$.`I_
M2@[FPR76^P>G[S;]'U/H+YC224_3V/?U![7?:,84N!`&Q[;`[3Z7-6U%]2__
M`$9/E[?_`$HOEQ))3].UW]4-]C;,5K*`*_2>+`YQ)#O7WLAK6^E^C]/W?I?^
M#2QLCJ3P?M.**=`1M>U^I^FP^ZOZ'_37S$DDI^HW69(:2VHN/8':V?[6]R%3
M?U%SK!=C"MHL<VMS7M=NK`'IW.;[=KK';OT7YB^84DE/T]C7Y]C"<C&]!P.C
M0YKY$<[M[%:K+RP%XVNUT^?D7+Y7224_522^54DE/__9`#A"24T$(0``````
M50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`
M00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``V`"X`,`````$`.$))
M300&```````'``@``0`!`0#_[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("
M`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`$C`EL#`1$`
M`A$!`Q$!_]T`!`!,_\0`NP`!``("`P$!`0$```````````<(!@D$!0H#`@L!
M`0$!`0$``````````````````0(#$```!00```D(!08+`P<&#P`#!`4&!P`!
M`@@1$A,4EM<86`D5%E;6%Y>8V"&4U%<9(B,W*&FI,20E-CA(>+B)R0HT-65!
M,E)D569G83-C)B=90F)#4X-4M,1%M79WMV@Y$0$``@(!!`(#``("`P``````
M`1$A85$Q08$"<1+10H(B,J&QD<%2_]H`#`,!``(1`Q$`/P#GP-L='D?E=Z<9
MWV3VY>;55D))>+]D>%)7>;/<$L+!>2X'3DB-I9BZ2TX=?A6<7@=$.HIU52G0
M1+ET`%QIX13(H2+"A9=9CIAF;YGY@`:^P$U1MWGR;FY[J<PF(%()VUTC$-<]
M#VJLRBBN=#<,ES,6P+2-/4BQ(SBUVTDIXN:X1'"',!X`<0(L..*S.,+K07LV
M3C?Q!@7W*>P$JY/MK[+^(_?;]-5G;(RXPFYI9%\.@.#6UV*$98FC*&W8W"4S
MB&<:ZH10BYA6,J!C#E1>($%C4F,8A%4Y['RLX-DIJ?\`KW,,PKFZ"WL5-`$$
M1DV'<^SS86-$C7A[K$C0RYTR&U0X6:5T58?9@BKAGA$C`;!6RR%R&L/C;*A$
M8ST;%?`Z>^#G>L_IT9R?(LLP.7@321RK*X^'T^Y#3T7:QWQ@X5/89*1EU^J!
MXV3<RBJ8E#;E3"F5P$P[<`+(,I;D@*0GMTB^K8+MA,&YT2O&!&_%!S6(T4G_
M`&1PA5`]H;,E4Z8048>()FE0%26#;;D5("'4\`XKQ+99@E[A99&+\`-K<&6!
M(B)MD',?%(])]!.@FQ'6+53&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#
M&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\
M4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^
M@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";
M$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H
M8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/
MBD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTG
MT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G03
M8CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M
M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q
M\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D
M^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z"
M;$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%
MH8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF
M/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CT
MGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G0
M38CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8
MM#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<
MQ\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>
MD^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z
M";$=8M#&SF/BD>D^@G038CK%H8V<Q\4CTGT$Z";$=8M#&SF/BD>D^@G038CK
M%H8V<Q\4CTGT$Z";$=8M#&U$NV5XFGM-]G/)Z)\OV[.Q1S[S"V`Y+RKV1NU1
MYU\/M:X_D_R?_)W#Q.4Y;Z.0XOYVHU4;Z/_0][B2V6Z@GW*J(J(F)2B\5D!Q
M.L\0)@%C3B72R"BM<NKJXP6&.9Y0!;K<($L11+Y96+%`L.'BX6M0=Y0<7`D2
M#-C*&!0K@?,`@EC!W`N%B;'+E\A<RX`QFV%AA00,QL[X8Y97QQOGE>UK<-Z#
M_>9$^>>4>:%?*'->9<_Y`+GG,^5Y?FG.N)R_->7_`"^3XW$X_P!/!PT'Y)D"
M*<&($GDBA$(8P.;%")E@2H8IHSG<4R9$P`PPQS,&!+WRSSO:^6>5^&][WH*'
M;M?I2\-K^WX0_N=;BU.&H_;X7\JLE`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H-`_P#6C_Q^/\G6I^6^W\O_T??Q0*!0*!04#W:_2EX;7]OPA_<Z
MW%J<-1^WPOY59*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0:!_ZT
M?^/Q_DZU/RWV_E__TMCD,^(IO>IF]OFK-NX4!P6]6\EITEA.206$A."(HPC!
M,<T(D72_-89(CDI(+/FL(=EO6Y1(:*Q@855-65T@Y87E39X&T=*C%0YK@\17
MQ,`6.HEU.0",2J,0:B;*;MM]X2'K^U4)\[31?'4]MJ-H?293B]8O<A"QA[LU
M7%41P&]F"<O?,OD&-8,6V=,E1PM#JKXANT,K[70TO/R2F<GP)L+LMN_KP%KV
MH,=N(*S#2/JI%9Q_MIY&GT&%9U&GBMGDD0)P$U0WF0+ESQ6Y4+"]L\\B3$5M
M&^QGB>;;1!)T]S<V'XRER%8KVGG#4YO:M'V&AW-KH48:8K,^(4RC2.1#S?`G
MG"]TW#$$J&9Q(FT\3DPL,<N,+BLCUC$+P>%_LWLG*DA2K%&PLGI,V9IVN^G6
MRK5?B<P6O'YA`OLU'Z\Y7%&Y@BS0"R*KH3?4D7'-&."AXJ(A7,3G(@]^)E@A
M/:(ZPS+>647P6F70H@#K?-"@4;.^80Z*ME%W7C!+D,4OJCMHFA$F>$?GHDM$
MC1TF=%4`KN`HA@V*$QL1!`S60!8<1WSV7-]NTI=R[9?I5IU\V-5/)[=I2[EV
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MT/*!-HMZ9"UHU^E6>5326>CB?&#6'<QLLY9"U?;Z",$`9*EKX*BTSIUE!SIQ
M;A,VX1"3?51K7X+6`O:][XB(N:MIFU=_U,Y_9?8&*H&2]"%PFH2>Z2[9*&6U
MLFVG`O`BCEC1FV:6BO&*HO;"B9M8M?@#.N!*!O;AO<>U[6QREM3Z5%V]"GMV
ME+N7;+]*M.OFQJL^3V[2EW+ME^E6G7S8T/)[=I2[EVR_2K3KYL:'D]NTI=R[
M9?I5IU\V-#R>W:4NY=LOTJTZ^;&AY/;M*7<NV7Z5:=?-C0\M&WM1?':4YYV;
MYHYQ^.3YR^2O+NO'/_+7X37D+V?<I[>O)?G?Y+_EKE^<^0/)OY'E+RA_$:C7
MGL__T_6PB^$;X=:'>4@P-7([-ITNK"<J.9%/%38J.0*)>*"8*MEJD030&#9:
M7G`WPU?).*WP`R4A+Y\')!%@2ZE^T\N[,^%1X=YMO,]J#:G1;YML1?6G,V48
M$JL%2)54<>:`*NXJ`)97!LOI*L*UT_,=.4.=)XF97'*X'#QKW4?:>6;J_AX:
M3KTB23*ZQKC':@_I>07.VY$73!-0RP<*6]DLDB/._D>RCBA)*H[DE/"+J:@1
M+%CY\+C8CC"6$$XPN>7[3/#STG1I/(S*G:W1J!(R:SB[#)KV289,`!MDLS,8
MY"+"-\T=&;1E1\P<+(N2B*3S41$OA+9#W"O?"XN>6<ZYZ@:U:DD'4F:YQ&VX
ML*O<\F*#KNB"JQTVM"H98R30BQI075)54,4I"+'1\")(,7`F2L.+R(6'*9\8
M3,SUE"N[7Z4O#:_M^$/[G6XM3A8_;X7\JLE`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH,?=3L:S%;JN[WLY6^SFFWR0BBO.AU+*<WFZB)X/!84^KK:N9*)J:2"OE;C"
MC"X88\/TWH.MCV1&)++,;\BQD[4!]L1UDKJ+:=S64RJR@+A'$P,5R-)BF2$%
M+&P<#)<0.]\,K\&>&6-_IM>@AK<?7;M::P33K?YX>8'M?9IEH^>?F_YU>;W.
M#9,UY0\W?+;;\K<3FG%Y+GQ;AXW#Q[<'!<L34Q+0/IQ_IKNR7L_"VR';0\__
M`&0/(L[O,SLZ>:OG#S<H<*^3_.+V[.3R3Q^=\;E>8F>#B\'$OP\-I34^]Q,4
M]1]5@H%`H%`H-`_]:/\`Q^/\G6I^6^W\O__4]_%`H%`H%!0/=K]*7AM?V_"'
M]SK<6IPU'[?"_E5DH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H-;7B*;$;PPHC1<U-&=4
M`=C)'EU6<2`*[5M5,EF)#HZ052S2>K/TCCF@)_DQ?!.F;%39UP)!,$<CE@)<
M7,4(+.-1$3=RUH-3P6=F=Q7"E2EXO&X#QEFX!L)82M9885<VM%#7S$RY7R8<
M5"9!*2@\K%\L2IKR&DDSV?(\;RR9O>PE*Y7[1'^L-_\`"4(11KC&#5AF$62D
MQY&3*+&BK::B-D<%*$,#Z@;5E`<4XI&CRHI*"DJ'AC)DT:'',F1Q<Q!!,L\K
MWJL3-YE*M`H%`H%`H%`H-`_]:/\`Q^/\G6I^6^W\O__5]!&I7C#3+LF7VN6,
M=0BZA:#TM06FC%;`F5C6V!(G$Y38S>&8DN15)ZC'CB0SP!AR'U<VY2)?)OEB
MJ.?3`KFE(L5LJ2VY]:K+&=AO',4((AK3N4QH*9QX]LOKF%L2J-YRRPM-8*P>
M*NQDD:*8O4D^,W9YV2(:P=XIL&ZF$CD,"9++/(6XF>(5+(];F8M9N$?$]=,P
M[4-J)<X$*(,$R=.&S>N442Z'(H2P[U:3-5F99YO8^YV,2;=V^E,AT%4M8`13
MA)?4!Q14[A&!#P$PRNM)]:CKE'<O^,(IPW*,NG5W7X%2U4AZ;I-UD79B2I$S
M'D`W-\5ZXJVQ;B(`1M@T1$D%K9)B*.E!CY+=S=Q\;C\CP8Y@8+/K<=<K(Z$[
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M[+T[EF.:LF&55/;RZQ),3W4OEBV>`.=FXVCC-`5UO.Y@7`/A`"SPPRRX<\L,
M;7RLLCUF>S4VD>.ML#LE-D8I.G6E;U[,)A\)%Y&V`FQNO$,%:8*8K@%GR`SR
M[#*+#>;Z^$4OGB0RY\XS8@M[7$3@K8B\26U]:C,Y;U>U[`WI`\O<W-'5]59J
M3M>P-Z0/+W-S1U?4*D[7L#>D#R]S<T=7U"I.U[`WI`\O<W-'5]0J3M>P-Z0/
M+W-S1U?4*D[7L#>D#R]S<T=7U"I.U[`WI`\O<W-'5]0J3M>P-Z0/+W-S1U?4
M*D[7L#>D#R]S<T=7U"I.U[`WI`\O<W-'5]0J3M>P-Z0/+W-S1U?4*D[7L#>D
M#R]S<T=7U"I:-NT%%G:4\I^5G%S/\<GS[X_L[D?E?-G\)KS1YUS7S2YUY0\N
M_F_)_$\H<C_&.0YO^=J-UCP__];U/:O>%,PM<)NF&=%&;YKF9W/YC+,1,M0E
M-=15U;944KZ2P0E!(6'*"@DU]_.8LI,4N"44E0P-8!*+@`\E<Q<R9'E-3[76
M&)2!X,T)OMBPTQ`)JG1F$HOU<`TS="@U3,<9GI<U\Q<3?=9MJNS!SQ\Y"B&K
M&EUO!#V4T0-.-87SRQX<L+88XJ/MF9IW"'X042LJ2U>1(WG2?X^`)*D[/2'V
M<AK;.,(,#RQL<RDQARC*3`4%5G'G4?7E%$("7*%%A044P@.;'$!+XWSO2C[:
M<56\&^"7;(*NZY$EF<)!9KJ459[/>(G"K,RS'>$S.>![Z\/"8U4V19A5WAN=
MULD48R;*A*6"9Y5&N-@!B%C@7Q4?::6*TTT(9.G"B^'&G2C*LS/1[M")(T$>
M$LF6<*J(4704W3S7B]BHI9DM%GI81)$2U(:YHV*`*=4S%\1C(N8F/&O4F;<+
M=K]*7AM?V_"']SK<6IPL?M\+^562@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&$H<E1TYG:[&"VW
MZS7`^6$"CF'RS41SHJJZ6:`X<E'%!%=2`1.CJC?P6<D<WS6YL(+E^;"<3C<3
M+@#-J#5C^#;HBL;02AMK),8F9FDJ3799X9HLL*GG;'#34Q"":6-AH+#&*ET1
M2*FSQ$0WQ%K!5Q+BF<L"]@0L0\,)37VFJ;121(FFDRB<G%"Q!/(%@"1`@2`"
M*DR1,J%@`5*%"H&`8!8L6`#QP##PQQPPPQM:UK6M59<F@4"@4"@4"@4"@4"@
M4&@?^M'_`(_'^3K4_+?;^7__U_?Q0*!0*!04#W:_2EX;7]OPA_<ZW%J<-1^W
MPOY59*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!015.<BK40PY)LI-Z/G'*ZU'K*<#P(1NT,@\70]!4!
M.'4LT!`L("9N,K'@B^6(`6`0PPHG!@$&()ECAD(>>+S*\<7Q0\>4D!P)GA9Z
MKKV'!FT6WFHG-A74VSPG*<BIY@&4Q[DSG-..5-!G3;*!&#SX<TPP'E>UYF6_
M\?7<MJ6@_A::O^'D675:("CQ<THO5'!2)#ER07.=6G4[R^*ABL"E\TPK<@U$
M8C=7MRV&)4C@9RM;&PY@QEC<2]IF?:9;(*(4"@4"@4"@4"@4"@4"@4"@T#_U
MH_\`'X_R=:GY;[?R_]#U00[XQ>HTOI$VO`+"5F3&4,)PSDM*;OC!TALB0&>`
M?8B#=<92DBD5@0VHF7-(287+(XN`2N9*'BIS`#D1L[`RVI]9BF1NSQ8-9&LU
M==G,7;TZ/<YLK&!":F<RHTB=4?[\;$3'SR(DXOU^MMM'CPR.C`K+@+$N(4S4
M#A@WE<(L"/E;@I9]9RSN/O$DUMDO9DWJRVLI'Q>7G=)\<MY[*K`54N)WO)\*
M(:>XY=C1GO4P);RD]([1CV0RD7%*EPL+%AK!BB7QQMG4J:MCCS\5'4R/IU=L
M%/!4D!#$8RJX&JZI<-Q^L^PQ(D1K1J<E]=B\>0P[Y@YOTA'9`51N4P+9`Y6P
MY'$:YB]@KK/K-6DG4'?&&-T\7F!&:'*;.7&,CQVZE5KR^PS3!<)YBRVC**_&
M;_028QU1+K#.>R4D&121H(;CWP"XV8>&(@5Q!,3#%]VOTI>&U_;\(?W.MQ:G
M"Q^WPOY59*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0=.X7`B--`7'2YE4BA-MM(ZFX'`MJA@,HFHR(C$AU%5
M55$V-?$(J13R!80883*]L<`\+WO]%J"D93Q2?#C/&BQ(MNYK/F9.&`2I?#*7
M&@#CF.8$Q""QR%&4@P0L<A,[6OEGECCC_#>]K?32X7Z^W#7_`+">/M`Z.\Q8
M0T8BZ0M_)_-\L73$2'DM7SCDL.%:^!HX*[R**MJSG))/*!CBBHR:;2Q`;WMD
MI%[VRSQEK'K/6<0VX:IO&?7_`*^QF[]HHO1H:GI:1C0\BQPW5<HMHC?4PE=1
M+)]TTZ377+@&"K(8)4[D5S/FAB0AC(N*)EF%EE>I-7CHL)1"@4"@4"@4"@4"
M@XF)\CF=%3<#I3-1`+AFQD_$R#D=!*C9YA@F12ML[CAEQ1`\L<<[XVQRO:]K
M7X;4&MS1SQ,H?WAF?;R(&",2#.ZVR8$WVP=!-V&PDB-N8%$(Q(:7EEGQ31.T
MDHZR7M<#&X0:6,E"YWY0W>U%F*ILNHA0*!0*!0:!_P"M'_C\?Y.M3\M]OY?_
MT?05X??AC;*ZSSMLY(\E2!$Z,TY+93J8::R(-3E]G1S*;E<J;'1DA-3CBK`7
M!B1LLM^Z`H$\BZ20P-C'E11O@+@FXE<#4IJ?:)B$,SOX(<JR;%FJC7275KRO
M/2)-*".G+V5Y.37\=2V$=3G(WW0D[`0&.W")%7$DUMFBJB5*`JO,2N94WP99
MX\83&ZECVBY2W'/AD;F0Q-"4ZF#-<#.2/H1E?;O8[7C.2TN1E)[.68]JHW56
M-F@SL"AX)I81BLE07U!0NH)"H*KJF1R^&>`')XY7)<4Q&1O"$V8FAS2&QI!F
M.$4+768YED3:^0,V4C/\Q**;L5+^IBAKL^T5II[BR';V<3E7"LF51-S-J5U,
M,EQ"^6%L^$2RE^T1VRNGX>&DLY:X/&2)1V(>,5.!\.6&M:M>6NDPX&[<VR2C
M_6IH+#83'0NGWF02U(=WODRKW-&B@!?$FFV"Y(,8S;/CX$F8G$='7[RZWZ\*
M$RZ%+9^!87.K4A[YA$G^KFXN8YE4?),[JCMHOG2CP/C(69MS%3:ZCE#HH9W,
M?`0V5!&RM<0/#+$1/7X7-[%VG7=.UH]Q,6^JM5+GD[%VG7=.UH]Q,6^JM"YY
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M`J"0'&HX::B(1`PJ*I\0`HT#!H;`F0*B"7P"#S$RMCP8XWOP6N+GEHUDGQ;?
M`(99G)/9.N[(GA4R,8$RR?$NEC+!%.F\[Y8<B3%E)NQF`;QQ%QXO&"R$L)PV
MN%REOIJ7#7U]D>L?Q-M&U*8(M19K\(AI:HZU20JNQ'QVCV#@UDM=MDU-#9:V
MYT9,(-\K"1M+6S:X>)DB@W-ET3F'/PQ!,<PK\>R]'UGM[976,R-X1VY\+[;Q
MQIJPM:I-F!FZSRJZ"Z<T=92S66DX4ZS5A*;JJW5UQ1:VB9U1!<ATH%A=.-"F
M"ID0.^5@\KXWIA*]HJW\]F+<&F))D>V?J$XW.P\7JUQ7RW&@'<5UKC+`6R0S
MK2FWA8XG<*X>0`S`97A,%[6&RQO<4.UN/;+L_H!^&6^_#%VP-.>'X)\,\6(V
ME&K5+.-+<NPFN\;CB.XL*JED0Z$&[5)3D9;<+A)&Q<.7S.JIHQD%:U[B7X+X
MXZAQ]KC,RL'OBFPAJ"TF$Y(I\(=K[C*#P<:DB*S:A'71HJBJS29%,Q/@+BX&
MVX<?(X2>?'RYN'<0(#"XEN"V=[_13P1G]D:Z&*;5VP=[Y0)V\$%D:8(+<;">
MX6LZI,BEG*X+U-'%3`D,@A$5C7F.L$94(DQ<#(@61DP-P<;'D[<3+*SP3CI[
M6DC?2$E:'F@Q#>D/A8ZC[-/5R.%32'0DN6-8<:::STS%+Q$1UX<=2#:H)PN.
MK9V"%#YT'P!VO>^8=OR[",]91UH;!>P$F.]_%M^/"BT,UR9:4VTL=@J$?L."
MWFKN=T&500-2)G;-Y[R3@03DY)"MG^>+%;YBB8\03+@RQL\$UV]DB[YZ42,;
M:;`)>'KJQX?B8\3#D4[R(KS9`T:")1%L`I7*)>*,$`S%#/,\;5K7#$_BHW!A
MP?3A;ARH1,=Y1SH7H)LFDN^05GQ"H8\-YSLP^@)A..FE"FO4:EU-$<A<_CFJ
M*RN9&A=O<JF'TV_$#QR4S>=AK9?F0\>+>XF8[6D/?/POCDV-B/B.EY75?5MS
M(*\L&WJL*NKL.NTJ[4(ZGE@4Y,Q*GXZ6N:F$U0`N+B)A8/AQ$RM?C<-N`1-=
M4>Z&>$(X8!=C]<VW3VUVVO(.UO)Y1":>>JL6-=*9+A#5<SZFJI8X:'<$P7-%
ML^;X!X$RN&&%K<7#&W!C91/M?2&?;[>#%!&XS:CY!C)4;NGYMFK*Z?6UF$8D
M:J28?:4N$"9.Z$Y"[=4&2$<*D!2=A2^1BYJP60@EL,,;"9\91'M3`M#?`8U?
MTH=K]="XK%MF@GLW$U``0INBV/5U+;`B>IY*.2LAA'""KB`H',<N1$RMCA>X
M=N#A_P"2E$^TRG?;GP8]$]PDUA)CFC8*&PF"L+"N7,:YH,:Q2><UEH@7(CI;
MO-EX]5A5=+*9%`QR^&'("@C6O>PG%SSPR41[3#7!LEX/$,:,ZE3Z;T9UOD#9
M_8F<$1.B!L!2079,KF8S37!D;%7I%02BJUT4DVCS>0BQNQ4^!CD:Q53!/&][
MA_1BI8]KF+G#19X>OAX>('K5MW#DFROX>SSD6(PW$$V)6:KZ8#.>:*/'[JOB
MC.!:!1ET=2+YK+3",8JQ+(/#`7,R1P"XU@Q!+91J9B8F+>[/L7:==T[6CW$Q
M;ZJUISN>3L7:==T[6CW$Q;ZJT+GD[%VG7=.UH]Q,6^JM"YY.Q=IUW3M:/<3%
MOJK0N>3L7:==T[6CW$Q;ZJT+GD[%VG7=.UH]Q,6^JM"YY:-NS?KQVE/)7L%A
M?R7^.3[/O)OLN8_,/,'\)KSS\R.9^0N;^:'GA_*WDSB\R\I?QKD^7_+J-7_T
M_]+W\4"@4"@4%`]VOTI>&U_;\(?W.MQ:G#4?M\+^562@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@JD1W*A-1W&7-'"JYF)-S?AI.FD^2
MQL#DEAHIY;LEB-W,SRO*!NPHFFR2KD3OAQLDL\&/C>^-LN`M35]EI\C)?$P$
M4R'!Q-C@CF0"N0N%C`Q<KF6"-#A`7RY00$L(<!Q$RM:^.&0N%KWM?+'A(BN9
MIZA775IEGU/$JL*(6<=6R;:(N20W0DM5)/N(^4/J!)"3S:N:+!GE@RGI)LQB
M6!XXURY487B\F$)EB6(F>B"8!\0_2S::15*)]?-@F;*D@)#3./A00&T7<.7(
MM9/4T9'/*F"J>122*8YJI.`F'F`$9S,6Y;C<GQ<<\L1,3'6'0[[>(A`7ATQJ
MWI-G0!Z+I%TNXDS49KQH2:JZ]3"B?17$N`'[H3D>#0QP0<2S7,A"'>6Y$,S<
M(/*]LA,>$1$ST5;\/7QH(7\2";WG$$.PO-+03F5':H_U!]R*3:Y5)O<LZ6ZW
MD=LCEVJONHNGKR^36C!T`,4Y:V028:Q#Y6P=\[2UGUJ.JVF^,P;?PM%K6<>F
M&N*)LU(RL_2K=7F6LN3%MAH+4,-AT*@CNL..HHI0R7)K:03*"89G`L[Y'<+8
M8Y7ROD'4B(GK+4IVD/\`4M.5?&0R.ANH<?%#)(MD&MKKS1E@DA<Z,8@9CG%1
M+VC5P5@Z'<H(+B$3(#<@`-:PH>8G$O4RU7IRX*[IW_J(YM3\!)#\1"!H1*'1
M;VR:T.HAI./I)(QCGD8S$<C=B)`71%$$0,/`,+!;,A6#X<L1\,[YVS9Y+].%
M\_#]TBW:UF?BT\=H?$.>NV;=/QI@Q4>,W"VW``F-Y<`5VTI$GP&ZEM_+`ZLL
ME2"8>(#9F$KGI_`[8<4WCEAD$(29B>D)]WP\/Z'O$+C]G1O,KLE=HH+,=HKM
M+&(D<;>;"LM7,HJ@@GVZOG7`T7=@:;"D24+Y&"P(9<004(/+E;<3@O4B:1?H
MYX2.H/A\O-Q2%`:8_P`=Z.AIYLM67GZ\KN8;)"$5R:V,&4)%TM'2R1D8VG`8
MY"A`8Y7"#XOT<;/C2EGVF>JY,X:V0'LLCH#>G^)&-+Z"UUD1PH"*_4,JX$I-
M6Q4XVDYJ0*>=Q$*Y&?)QX4.U\\<K8VSX;<&5K7M4B9CHKK+WA]0VMZ_2]".L
M;6B3318F5H&8^<LG0O!3#27($R5LR2L[D4$NV[,NYC-S(Y7(D(,,9SN!B+<7
M#'E\`A,!>;G+1G'W^EO28L?;,DMA[XOQO/:/W2@O1HKI.$4*QI'<C95"JRBJ
M('&DJ^&6910)AY\7*U\<N#@RM>U[VJ4U]]/5\6Q,8EP,38H(YO$$+$T.6`S*
MEQC%L,;#B@%13)P0L"()PWQ#R&%RPQO:U\\KVXUZP^U`H%`H%`H%`H%`H%`H
M%`H%`H%`H%!H'_K1_P"/Q_DZU/RWV_E__]/V\1YM;K1+2[)[8C.>(H>[@A<V
M;*2JDMQ\("B<8MR``8Z@<7PP3M[%4<AGEF`.>M?(D"<+F"V8N)@L8""+4\.P
M7ME]?6M%;7G%R3-'"%#[VR;N#/DE5=:219[GS=UN,V`T);,&<":H*NX<.17$
M'+/(7"U\L;7QQO>PJ>CE(^QD`.&7%Z`D&:XL69O:Y&ZDXXD3'XV3LBHA'$$N
M8%'4F@74A%TIB6+'`!1K9@6R`",`YB6QQ%#OD*FK[/D+LGKT#+HT`#3A$X,X
M%TD9=,1&*_VN'(@"272LU\P<&:.:G9<"P`;X>2AGCD#;/%/QN9O:P%N4H5/6
ML.7#VP<%;"):VMP3,,:S"D-I8S0'`I1L\V^\B:*LX8<K9/4QT$^>#)F!@/S@
M5L[XV&"O;,.^6%[7H3$QU5CW:_2EX;7]OPA_<ZW%J<+'[?"_E5DH%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H,<=SP:;`;*V]'TYD!F,]M)X
MZJXG4ZEA/0&ZA)A:ULC"@KK*J8*IR<3!M?\`*$&$PPMP_P`-!I'4?'RUQ=,V
M*D3:SP]/&US?9[0?+HD*5(@8KC4VL@FFXU5]5;*(B)9=`47&X?/-VI!=""41
MBR:E!F%$`4`P<PXV-I;7TGO+P'29L9+,X;"/;8=^.MPWDJ4W<I+KM5F4?.M]
M2N67\K$#;<;.8(Y@=.2"B!?%+(%,LA@PB000.5A,,;VOEUJHIZ5O#C2G9K[L
M>@RUIIX6'B!ND5XERC`=DZ;:24"03@HU=CF;BF[5@FA),&1VTU98)IZ6$(7$
MQ7#%N*6#_-Y9"97OKPQ.8S[0]@>P&M$#[4,Y+C_8:,6W*[,1'.3>:6W72$:&
M3B;I3TE;0B2T&&4-%,\C99(<9X#'C998VQ,9?1P\%[5B)F.BG,N^$MJ"\(><
MT80A'K8U"<[ER1"PDVZXLQJL>8B:"0<"*KKC7P?))-"<1MO.HBC\U.$QC694
M2^>(N88F6'%RE+]I[JE1Q_IO/#49YH-2?B%-$^*M\Q!SIZ6)=62N2@:$MPXB
MFL(L*1GD+@7RX.3PSSSXV.-L1;BVX>%4'WEM1UWTNU3U,"4L=<H&CJ)32TGD
MTI;66PAAXN5;32`N9@H16G4H9GG(KE@3&=Q+8&38MKB?E7X<K6O529F>LK.T
M0H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!H'_K1_P"/Q_DZU/RW
MV_E__]39CX;VA,HEY0W&BJ9],@6YK@;C-Q,HZT9VPB24U1%E;E(%D%FQ]%<O
M(N)-U2;$^9MMA+`7E,GY/(")*.+R]E2Y[E8Z3/3.7)VO\-O?B5]`-(6.T&NQ
M%DWKCKE"C>4]?',LJ!.0$*>PI%CC%TOY`.HYT&/U@TU(^0ATO.ZBJ"8%T8^M
M\R#S-F0,J4?:+EG\3ZZ[EQ+MXCOU;U!7'DLP)M'XCNVSDE5HN!AI#;GYN;.Q
M.,WXGCJ-5I6=8"H*[%!U*_('4Y83R15%*))43EN'(7#`EQ,5?"+)LT=W/G:0
MID8"-K8Y&&[YJV5F3;-)V?<+B8X*$Q(]EG0]6AY`@A0=+<=@CJQ=#,E!9LDF
M"9=+$`$YMB<P,6*\8?,1,14VV"^$?`,TQ](\U2?(NO3AUC;*GKGI-K\09#ER
M9!92>TA:Y1NY&Q([\"3&&NK*>(VP5)6"*HRD:O8PIDA+B6Q!XH@.*$]IQ$6F
MG>6(%,U,NA2EC-4T%`W9OF$6+)91=:6"6SLC.J.VBKB:9P(K)&,$314-/R*!
M7-"G<;%#(V-\<L\L1,!$]<=ES>SHM]YK9?I7'W5A52]'9T6^\ULOTKC[JPH7
MH[.BWWFME^E<?=6%"]'9T6^\ULOTKC[JPH7H[.BWWFME^E<?=6%"]'9T6^\U
MLOTKC[JPH7H[.BWWFME^E<?=6%"]'9T6^\ULOTKC[JPH7H[.BWWFME^E<?=6
M%"]'9T6^\ULOTKC[JPH7H[.BWWFME^E<?=6%"]'9T6^\ULOTKC[JPH7H[.BW
MWFME^E<?=6%"]'9T6^\ULOTKC[JPH7H[.BWWFME^E<?=6%"]'9T6^\ULOTKC
M[JPH7H[.BWWFME^E<?=6%"]'9T6^\ULOTKC[JPH7H[.BWWFME^E<?=6%"]'9
MT6^\ULOTKC[JPH7H[.BWWFME^E<?=6%"]'9T6^\ULOTKC[JPH7H[.BWWFME^
ME<?=6%"]'9T6^\ULOTKC[JPH7H[.BWWFME^E<?=6%"]'9T6^\ULOTKC[JPH7
MH[.BWWFME^E<?=6%"]'9T6^\ULOTKC[JPH7H[.BWWFME^E<?=6%"]'9T6^\U
MLOTKC[JPH7H[.BWWFME^E<?=6%"]-"6S/BL1TT9&,P'I3(>Y>\DZ)BB,`Y2T
M=.=D)T6L].1S6.+I/J;^]CZA95#1"N.68IPF6R0"V-LLS*H#8+/"\;B.\Q$0
MV!1\M:>>(,6G+6QG[IS!.A1%9:<D3<PBKQC]61;-^02ZJFCI19SI,;"MIU9$
M!"(@!L^W%-0+IQO('BF\!L@LJ,YBII8^%/#ZC37%B)T905)TT18Q4O\`++MY
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M1V=%OO-;+]*X^ZL*%Z.SHM]YK9?I7'W5A0O1V=%OO-;+]*X^ZL*%Z:-O9`I]
MI3F/MIFCC_CD^:G/_+K2Y_SG\)KSB\\.4\R>0\[^0_DSE^3YKY-_(YOROYZH
MWV\/_]7W\4"@4"@4%`]VOTI>&U_;\(?W.MQ:G#4?M\+^562@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4&G3?CQB8MT^DHKK-&43R;L_N$O%TN[?@
M^/V\NE2Q85PD`%!NC+;F\B*(BCBJE#-A0BR"36#'`'G@8YI]&=2VH];SV6OC
M"8-P#^CN<S2KK:AHNWI&-WJZAM<$5W!%TA;="**N&6@VDYP$S+Z%23KO1"A+
M.Q484R.5.FKE1L@\L<LL*F+J\-!D7^#QNCNXJ.=Z[O.5BZ005*#T/24[M2]3
M4!NM]TR`OK*J;7!E:6G(0R6DL^MW,J68Y8POGG>;3\A!0`227:_)XRF_M$=,
MR]%&JVE.L6E;+NQ];XE;D>D#6`/EU<!P'5GH[#(6.%N=NQZ+(QYR+N?*8WS#
M!%,7*EKY7Q+A`X<&%JQ,S/5:>B%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%!H'_K1_P"/Q_DZU/RWV_E__];WYAC@BYCAA#!"9EA;
M`&<`Q,,\RXV0()G$$?'&][A"Y%S`8EL<N"]\,\<OX+VO</K0*!0*"@>[7Z4O
M#:_M^$/[G6XM3AJ/V^%_*K)0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*#75XBGB/1QX=S$9JZZHYDN67Y*JFLMN)8]CQ",C8.IUI!4B8NE+3LS*FDUL
M`C^4@>);`$^I#X<IF5(F;`C6P+$6T;PO_J,9?X9(0):UR299GI[N-%!UJUHU
MF,K*^YD,GF14`%9OS&XPBSN#*JP1DF7$Y)-"4%\,[F;!.HR6%@!4MN?3B</0
MAI@<EJ3XM:T^[5:TL/7_`&N=",HMEWDT,J@J;B!C].=*XK,!$,.D`^ON4NF!
MI"MB9&2#I^]R:H,:SY`#(2X>-8GB)PN;1"@4"@UEIOBXZ3JN[!S1,I)8.4I%
MP<$HNZ[\R]F*A)V)T4L<AHF[>>\F+(I4/''\SR7,A#M\D[$Q=2PYG>6U]9JV
MS2JR4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&@?^M'_
M`(_'^3K4_+?;^7__U[D^%GBIR%-F_$'I\S[-.,ZYXC>3Y<&RK-?4C1N^"ZNC
MKT/FDY+F2,Y/2'3@QYZ4<PCZ5B>3S]A\"%ET@6*\T"*G"DCNZ>WZRZC9-UML
MAJ/X7S/7Y-GUG3P[=+H_),IR7>\HLJ$-8SME1NJ"OL^]@HP2SLCO68\BB,:0
M$=&`P-@#%\A\S88-L0LQ7!'7VX3#!,[%8P\1$209)E.;#<F,_8_Q%UO<`,S>
M5W&WDC2)G1)FKZN.`U&*4142@4?YJXJ*9:8J8CV/'#9X</@%RR!QL[D_ZZ1/
M.TSRJZMG9L>D!O:=E'>!QSS,J["+10CLK)Z6H:`*?A_+*_"K@38S4RZ*C%$0
MW)!DH:L*.G!&R[@RX;96.\.>0B,1?1L3\#)VI;B>,]%8@>#X>D`EX!TH5%XV
MZG(^W,EI>V2S'#F%V)*IAQ_G#1LJ[%!8`+&'(6(7N4!.\CPXA<8+"Z$]NU]5
MQMY2VQ%YET*R(+<+X(HF^85F`$;:[X$5"1R^J.VF1+)XF`7@$44RN"%B;P%Q
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M$$A(48HQ984FK'4:2$INH\"=5D]%"'+EE.5TLJ&F)YE3#,*!CE,KDR`8QCDQ
M+!7PO%B(F:4MTKG'QLMKI)(S1)L30=J9K-=H'R2/%4EM=S&'L\UE1P)F$MVW
M3,E`&24\9-'+YXX7.F&Z0$)&OR21X2V!@-E9CUC'=,_B#>'[M%X@\5M:(W;L
M-'L2-Q%>H#E7Q8N;$BDC#S0LTA31E5HKA93?IU+,DCH"C80(4<`QB7%#^D$7
M#//"Y(F([,IU"\/!2T8;6:!KDR]2VFIGB81-QO\`46)*KADMW8!Y8"Y6<;X5
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M2$Z0%XF6,G\',KJI?`CBA!V$5BQ^^>6>/,PLSMI3I]XJWK"CW<_:>#0V;"&Y
MX<9:UNE)(H;&:\RS0COZ08:F@TE$2R017<=G&V\D5E!/ITXE;&SI)S$&FI#'
M!L^2*9<:UJKG43F&R8L%M\<+@&RCOUA-%#0(1DJ:+,F3QRYDN/AB*`.`.%(^
M08P(P>5LL<L;WQRQO:]K\%5,;??F.XWI/K1T$E+K%H8V<QW&])]:.@DI=8M#
M&SF.XWI/K1T$E+K%H8V<QW&])]:.@DI=8M#&SF.XWI/K1T$E+K%H8V<QW&])
M]:.@DI=8M#&SF.XWI/K1T$E+K%H8V<QW&])]:.@DI=8M#&SF.XWI/K1T$E+K
M%H8V<QW&])]:.@DI=8M#&SF.XWI/K1T$E+K%H8V<QW&])]:.@DI=8M#&SF.X
MWI/K1T$E+K%H8V<QW&])]:.@DI=8M#&SF.XWI/K1T$E+K%H8V<QW&])]:.@D
MI=8M#&SF.XWI/K1T$E+K%H8V<QW&])]:.@DI=8M#&SF.XWI/K1T$E+K%H8V<
MQW&])]:.@DI=8M#&SF.XWI/K1T$E+K%H8V<QW&])]:.@DI=8M#&SF.XWI/K1
MT$E+K%H8V<QW&])]:.@DI=8M#&SF.XWI/K1T$E+K%H8V<QW&])]:.@DI=8M#
M&SF.XWI/K1T$E+K%H8V<QW&])]:.@DI=8M#&SF.XWI/K1T$E+K%H8V<QW&])
M]:.@DI=8M#&SF.XWI/K1T$E+K%H8V<QW&])]:.@DI=8M#&VC;FVQ':4X/+<+
M^5/QR>3Y3S7?',//[\)KC\\Y'SPYQYH>9_YKFW'Y[Y2_.\OR'YFHWBO#_]#W
MRD$5&2C2T>3$E,3CKD4PEIQ'"!`J3-+ZR`C)+=`5EHP7"#&55,%OH!$C@./<
M07$F2`!MER8(>.(=G0*!0*"@>[7Z4O#:_M^$/[G6XM3AJ/V^%_*K)0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*#CFQ1BY4R.7*BGAP2XPH!(`0`(8X,&'EF&5
M!%-"@%0Q3&=K88Y"9X!VO?ARRM;AO0>%_<KQ\_$>=FPK2BB'8-=6KH+=?K95
M2</GF8INN<)9"3%P`Z007-FI(0(PS;=GDWBW3V\1!YV`(*!D?.@9\-\W+K'K
MZUF6SPCK1XQ?BAGT]Q[<2V-X=NL`R@16$S7R%Q1P)C<)$F;!/IOG<?P/9J)(
MYE<N")G=>/Y!E3H.(N+=!RM;@N99OU]>D7+TPD"PA(B2)C'C:F,4*%BPJD?Y
MKSY0$`!P"S/'>8E2)+G9O+"X@G(@@A<?*_$PPQX,;5ARZ!01K*DRQ)!K6-/>
M9I,8L6-$IB+<5Q/YTHS52LA`@LALBQ8TLG">!T]GAC^;+@\H.+E>V.&&65[6
MN.JEUM[WE,'`5TLU8EB?B)KBV)S+)08VL^M_("<CC95(/F2D821GZF!W'ME@
M*U6@MEC-L<K8&+8VRSQ+5=9+:N[<3=P&-J-OU9F-LSQ<C4):2IBA"39R#QY&
MUB2[.Z^<<4_N+`3''.PPJ.>9X8]L_P#9\,;6QJ+<1TA9>"M4-<-:"9TM!L.L
MF/CBMPW7W*G)MU!].D3(7(:X[QD)=%57T\37*9WO854438EO^3+@JI,S/65A
M*(4'3.)N-YWH:HV'8@HSG;2X2&3EMO.)+(K2&L)YC'B&""HDJ0!D@H$A\/HS
M"&#SPRM]%[7H-=X^DDG:]#F%WP^YGQB=%L8'/#ZHS0&MR1J>J"#BYCCDF07#
M.>TK77(R8,"BVNUCQA``SOC_`"")C;BU&KOJR)F;_MAO.='BG<9A+&FTPJYO
M!+0[2$JEEJ`Y*4L[7S`PB#8XB4(,!S&#@.0>6"2K>07)@(+R62;QL;WO4KC+
M8+CECGCCGAECGAGC;+'+&]LL<L<K<..6.5N&V6.5K\-KV_AHC]4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@T#_UH_P#'X_R=:GY;[?R__]'W
M\4"@4"@4%`]VOTI>&U_;\(?W.MQ:G#4?M\+^562@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@^.9DN$,`7$'!#,&>5YL!F+A@,8Y'&V8W(!996S%Y+"_#EQ;7XMOIO
M0?:@\L>XOB/;F;*^(0I>%?I5)T$Z\EU"YE)-;&A/$)^.IQ!%6-YYNE-:ZLA$
M50BPG4E)>!XC=*"*>705,AE<-3)<..=I?9N(B(^TO1MKM&SRAV#8KBN0926)
ML>4?LM&:B[*S@3KI:X^3*,6L3"7%<H(J+ABZB,4##P&&'.FS)G/"XPPP@HF>
M=ZS/5D^44QAE)7MESCQE"2Y9K%V/A)PC81A'Z"S2IY14P6L7=N9/)=+H%E!6
M,#9%`Q\0,Q!;Y98WOP<!&?T'!4U1,14\XK+*B124I.+B&U!34S9<@GD2H.-\
MQC)PZ:$"+%2X6%N'+//+''&WTWO04&6O$@A5=5U!H:QM>3=U7RGFQ$PX0UH;
M(3GCI$5,<P@\2SMV"<:@V(";=@\Q>$</)QC'@@\,KV+9Y<3#,M3WPZN[-\1J
M?N-Y\R7&&CD?'N-81IP82*3UL0,GC<J6,$U&8Y)0"$1,E0&+7Y3'))9ZZ*6$
MRM<(]?+'C4,1M)46>'_K#&+I+R2>9:C,LS@98"WG/8ERK4Z2T$8#%$$#&0W/
M(9I9"8H86.=@\"S<+(Y+`/#''$&UK4)F9^%T:(4"@4"@4"@QAYLEFR,V%AE2
M"TVV^6<X2F9!>:CN1$UQMQ9)"7M?,HJ(JN6.)Q\O?+&U^(*'E;AM:_\`#:@U
M\9:<S;K.)FK:`R\30&4#P#&-0-B3KH?>OQC''+.^9:*GT&94Y6UY'$Q&$N&7
M("+C8#%XG`B86M>]1J[ZPSF.-]V6,\$B']GF(YM-YU6AN9-]FS"I(IB.Y-/X
M\'*X0;.R./>.92XMA0OXA89-<0?+8V&2@;WJI7&5]:(4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@T#_`-:/_'X_R=:GY;[?R__2VRZ);K;]RD^]
MNHT>>RL:KL^WC)?E:(VVXX]9$E:P8$$$>'+&GU!\U0$\"P3G:)%B.?/"S9/"
M9&>>*"8J&!LS`BX#G,MS$8PZ^3?$-W=.P/`#A:4_D8V=;?\`"15?$)D1VF(M
MBEP83Q)R$_H\9]XV6DM=:MD9I-Y3)+)L?/S:#33UAS>%@[X8886H5%SCNF?4
MWQ"MH)7VPAM?D*6VX0A;8+:'>O7D;6M093&1LH6;NK41`O\`:3IQ?)1*#?AI
M\C*")GBX0U58.)?(K8=RQ<&V(7)"8BMHWV.\2_;V*I+V"F5GRFVU>-8NVOG#
M51KZGF8]9QHNLH4:Z6N">&]-'GRG)9N1SA]>?"4'<,+%9#3ABF>(>)2W#GR0
MB(FH7E\+G9+9"39'EB*-@)DPG[%-UNTNV-;+YO'[`CXXVCNR4>.)S.M@C$XX
M2$=$5$,B>2@!T<<P%=0L6R$L,*8M?'/%">T1B8AG>\LHO@M,NA1`'6^:%`HV
M=\PAT5;*+NO&"7(8I?5';1-"),\(_/1):)&CI,Z*H!7<!1#!L4)C8B"!FL@"
MPXCOGLN;[=I2[EVR_2K3KYL:J>3V[2EW+ME^E6G7S8T/)[=I2[EVR_2K3KYL
M:'D]NTI=R[9?I5IU\V-#R>W:4NY=LOTJTZ^;&AY/;M*7<NV7Z5:=?-C0\OYZ
M^[_BB>("I;DRHJXS-/T&9Q7.,IYQY$)]VADSL/6-*"JV16NI$T'@0%<XG(&>
M9'.XESY7$,47$N*($+<07-NL>L4]`VOWCI;;LW6:&U"0/"_W+FCFD<-D-6V+
MQ3GH5:<KFP42Q@T_DY9!A0\AC$7""6$.X9@G!PKA<.5L\L;7RJVQ/K%S4P["
M0/\`4Z)S43F(&DZ,NJSN<N3H"<S/D[8%HQ.?:@S?%1BQ7$*QU@.13/!*YH\:
MP#R4"2-?/FEN0Q,7R&Q++/IML`T4\6.6]Q;/NZUX?DG,.S;\UO->[*G>"WY9
MX^6L'8(L\E>4%S72V'D`-N!Y7\E^7.&QC.YGF=L`><K2?6NZMNS'C\/Z$I/<
MD8,;PQ]FW^I,EPN!L.\Z[ETJRR99413N!,&[=4(W94]MUTD3=\1<LS(*B&!A
MQ,.2R'QSOE@O2QZW^S`X\_U)&5[*YW8'PV]KXK0B62;Y/5H\X95L/B9R.`GK
MJX;U9L$$T;(`US,,M;`R<YU<P)QK@W"PQ'7H^G'LV%;9^(/N#`RBR2D1>$]L
MO/!9RDEPRN&_:!'29YMCI@Z8$1+\6%,-EBHWE,,Z+EPJ`Z0);D?S(9BUQ,@G
MA(B)Z^R-XX\4S9QNQ-/<];G>&A/6O$61$AMEV)QUK.Z-'@M'&\K#+V"WY82)
M,=,'JXB@@X@)N%@TPD=%SS-"<X")\4+$59]8Q$2UI3A_JN8G333=QUMU>D-Z
MD1BZC=V"S@NMN,#2>:P$)V2`VZ`PE>705@N8!R,7,YF1".0.6`=L,1;9Y7P6
MU'IS*TGAM>/PJ;W2D\(;.Z>/HJ_D]JAO1HI<0OR.',646^D',B#T-.=3F!V0
M>GHHJ:95DBQ`(F(HB'+&#%\[`6`PY9$I[>E1=KH[9[P[Y1,HLDOKSX7<PS`2
M6R2X,Z3+MD6)4@1"-$1TS!*`)8Q*^)F+CX'PC(^6=SPI#/&X6/)8BVOG<,D1
M'>5'U3Q_7EK"<LG^)%H!/6MAUWE@3D0%HZ/,R2!'>52!3(#Y'6[/1TQ79%P1
M!3Z3B5YMS_G-S0W*<AR0?++Y7Z7_`*RJIL-_JLF(3&;&&J&M[N<9<0)3R>9C
M8;-&90Q,;',G9&!;!.-WJ_\`!1"'PR,9&A38Y6X5\`\<`Q./EE@M8].9;*O#
M&\47:O>*.GO+3ST9<6,=EU9)0XW<T(OF)S)5?5B0KA!?Q-?*S7,48J)3-"%`
M3+%LB8)G`7G`W*7PXH7'1+/MZQ'=Y8M^/&YW&F#:EFOY@&L=;E?5XW+S"9*2
MU#)-P"9*;M-*K.>#B=999LX&PKK9QL%"I,,'B'2:>.6R,$Q>4$L+:6Z1ZQ$+
MIZNZ=>.)L!%0B'*TO;)(6J<\.$W+3N76!)\&O.792+N9#0D\,PGK;[G2.E\"
M/GDV4P"Q<#-<\C"E\[&/)AH(7'CLLS/K$],M^^ENF$!Z')Q42#O#9V('?V)3
MFJG,C\=>F3NE96Y0+D35\'*:VF``;)0Z'P6&)HA9+(B\%KY@Y9?E7K,S,]9;
M"O;M*7<NV7Z5:=?-C53RI_*7BT15$[Q#C)4UZV4?$NC#8@!PQ"HNLDZ2\%G<
M2V&0JG',1[+O%T-\D%]-\S*D7)EL;6X+B<-[6O+6/6W2O_8CQ/I,,D24'Z1J
MD!QZM%\Q<Y.E=TP)*,TII(>XH0>1;7P#8F+68W5[`.V(P5U)Z*H0=\K8CDKW
MMEA3)7KWEAB7JQ@[5`BYML=;=ZMVW:4,`J(138.2=+S$,I*ICD",8%;&M;*V
MA:L%)Q3,P7#R#Y^B*IX/$+"US>=[7RR%\87Y1):>[92$YOMO1;8)OH*.4!()
M*(B+6EZ2D)9$OC;`N23DTAM87)$B@&%N#`,+#'#&WT6M:JGEVGMVE+N7;+]*
MM.OFQH>3V[2EW+ME^E6G7S8T/)[=I2[EVR_2K3KYL:'D]NTI=R[9?I5IU\V-
M#R>W:4NY=LOTJTZ^;&AY/;M*7<NV7Z5:=?-C0\GMVE+N7;+]*M.OFQH>3V[2
MEW+ME^E6G7S8T/)[=I2[EVR_2K3KYL:'D]NTI=R[9?I5IU\V-#R>W:4NY=LO
MTJTZ^;&AY8/([I.3`SU>/I6\/6:Y'8Z\#R"PTWJ;TG<J`H86M?B9&$M6VH-%
M,A@,K\8(2V-A`L^#+#+'*UKT.G=1$FQ-V-93I(WI%"FQZU&89L`([J;M;*>M
M3JBY*2+Y\`H4.S<3V;>\RP_D1!MP%T\V7=J#C;*^(9$O:V-[1<3U3<W_`!1D
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MJ[93?$,08PF"Y9BR,`/-00$,F2RNAG2J6&H-)"P`"PQ;C.4E%+LHF$PGR145
M1%S'OAPV#L&69F>LOD]-"--)':\2LM^ZX1:[VI!22`@1,A.!O!*:>S&^7S21
M,&\0"-""7-H&8B$3R$(FKCE1LB^%Q`\KVH7/(M:$:9N%[R5)"SK=%1U\S`W'
M"TY)<N3;`!474A.U/))3J+'<B^0(1<RYDY."!4#1?$$V<#ME847/E!.,+GE]
MT?1#3A`D8C+:5K?$Y>1TUH$F&4=@C6)'%$-IIS*+QN42A,#MC)0QR<?%0T2X
MX@>9G-*QYKD)D#>^%Q<]+9K`FK&NNKB:XTG7N'6/$A!WJ!)3<X3.2`T\1<-I
MA7,DE>43660QLP62"@P@9,"^?(%,!<[`X8<?/C"9F>J`=VOTI>&U_;\(?W.M
MQ:G"Q^WPOY59*!0*!0?@3'+,,3#$3,'+/#+'$8.P=Q`LLL;VL('88,4*^>%[
M\-N-CECPV^FU[?10><5V?Z8;1I].ERO9WSSNLX'8\7`LNIT+RC(T)#*"VXG"
MHF5=;5SXMM>,;"G5)2-BC"Y<%N-GG>]2F_O/$-V.INM38U`@)@ZZ,AZR._69
M&I113&JM2LK-Y=>)9%/*YY7*H1A5;+69Z<82T+)0R+$,.9VS+D@PP.-E@'A:
MU9F;FT[+:`A.4@*E.-%25]+'X>635M.)JI`;C!B!9<J3/`CEQ.$(7+&_#C?\
MG*]OX+WHBK3W\/\`T8DC(05\:>:S.,X+?C9JAZ$HZQ6N&]^'*V*X6;P"N'CG
M?Z<K8CVME>UN'AX+46YY1Q?PQ=2$Z]AF(C31#QP//',`W"FT^SL3X%K\<3//
MD4IDRZD(%N4Y<7AOD3RRQN.+EC?'(3/+)1]I?GL,/E"RP,1UX@>]K,,E\>`J
M777Y#TS(_&O<OPW/E)QA&1%-0QM<,3+&USV'!D->U[W#Q##P%ZA^K0=XA;<X
MHS6WSC1ZW+\7(-/FW3A"4\%#B\C>X1Y6AJ8H6R*\IEAEPB`$_HPSO:V'&M;.
MPN.'YQ5?%-;=[C&V5H7+Y<OEAF(72)!GZ!5-0!PQ+Y"AD@U6/M@$XH;'R#%Q
M#L,9N%ARV%\L[\CE8=D_QV6V8W7;V-A7OX;SN6"X.-Q#PT%[.P%(>00(5A<C
M`I$E*BGKXIJ>6.!?*X86`&(XW*@XXA\?(7$$5'+K\]\VPD'KKDAZ6[VQTIE2
M@Q`PM'=4UB4#!%/`&,BCEQ5K7I5F</%*#&!$$OE@/D6X+V$XW%SQRR%;AV=O
M%*T-*Y6P=$_$8R$XU\+A36P95@L;#.UQ;<F*#,;%8PH(M\@;VMCG:V5[WQM:
MW#GAQEGUGA)A>9]$]B,TX<I*^I4YB$<1P4@8N^H=DW,IB:$%L9"3A`E1;R+X
MF!4O/E,0KVX^1;+AX;AWX!F$GXZ[:\YXXYX05#.>&>-LL<L8Q9&6.6.5N''+
M'*R)>V6.5K\-KV_AH7/++6I&K#CYJCLN-&BV8P;0OE`0!)CINH+03D\\IX7Q
M-*I!+1TTND@J>8G`)<6X&7&$QM?.V7!P41XWY+\#3PV$/;E"U7=/B&R.B[!2
MR76WBWF&JH;45C^%SQX(XD-]P.DX+F"$]'66.BCI94^-@H*X9407'&^8Q>QB
M4Z?::NL/3.T%O4[PP-=(JA!]STF-%G,5&P;;#"E1Y%U:0W1B:43IL)(:C=+X
M#.]W9V/F1@D]-3"9T8L6PP*@XW"!PQQO1C/M-L6MMMLS-W`6U)T_=A5NG.+B
M6G7<0\?UXCNQ8?DABRVVHGQ2W#L*^"0Y/.X@81Q#:P`W#CP',;7X:%1WE^;Z
M/2A,^/.=TML9-EM,-XV$.0A!-U#5O7T+$Q8(<PD*)1A.`[-D@II0T%C8/R\\
MS)8;##AS)X\?+"PN.T+E1'!T-P&V,&9"<6L**6MAEB((BL%K(S8)FS&-Q,KG
M5+%)*%LU11%S&SS$,F<A3`N8F66>>6665[DN^J4Z!0*!0*!0*!0*!0*!0*!0
M*!01Q*\01;.K'5HUF-@-62F&N8A^4FN\$8FM)0PP%[Y%#P()L//(BJ)XM^4*
MFP,@C146UA`A,,[6RL+KHHMEKCM?JQCDH:>2Z+-46)^-Q>R9M6YUA=&()P%N
M/Y%A'9H?%6D%FBAE0,"Q!.=X;I2,+WMC8<B%^7C&KB>J5X<WQAZ2'H3AJ0TU
MWZT;&F,,K80#L$F%&6[W`(#EB`8-1:XP3ZE'DV(=S/'L$;:BNJWY+#CCA%[\
M.%JE=^R[-$*!0*!0*!0*!0*!0*!0*!0*"-Y%F2(8?3KJ\MRK&\6I.(.9G)4D
M5\MAD)UBX?&Y0Q<ZYE1,+6!#XE^-GQN+;@OPW^B@U+;J>,Q#\7:]2&\],P5'
M;R5DA.4K)=XO8LBOB(F*2(E#PRY)DDR:VFT,Q`&6QPBEQ3)8)7P-'!;X!VN"
M7YR<*RVH]<YP\P'@^>*3NTA[[9)2CC(^UA+;E]!92['6!W`TL673.)4OE++-
MQ."DFZT#;`;J?;`R%EFGH5VX3L4'R+!%"1DC(EOV]8KX?T,*TY%`H%`H%!H'
M_K1_X_'^3K4_+?;^7__4]_%`H%`H%!0/=K]*7AM?V_"']SK<6IPU'[?"_E5D
MH%`H%`H%`H%`H%`H%`H%`H/SECCGCEAGCCGAGC?'+'*ULL<L<K<&6.6-^&V6
M.5K\%[7_`(:"OSVU*U4DO+/.1M9M?'_D)E;(3)[0Q'#JRSRQN#?'+.ZZVS]\
MLL;EP^"]_P"#B8_]&W`6YY0!?PL]#2PEA6Q`A:-!,>'D\X6D.6H-R!OED!GE
MD7O#S]8]RV=Q"]LKY!\6_'S$RX>,*+?-1]IY=:J^'N*G)B@%$FZ>]T6+%DXX
M"W3)[8MPS6@(RGD7#LEFCS=GLM)&:TE$#H&&8A+GA;E@;B`XC!8YVRP%ZAX(
MMA?#J\0M+\0L?75XHKRE'9F47D:>;3E0H?4QTZ3$X=3S.B3*3>YODO)*`D\E
M<PHF3`@`B$(!D"-B$(%CA?+K$Q5]G]`/2W0Z+-4&"SQE5#:DC[)8MLB6EG9E
M:1#*M*,ENO,"]UM7.O5X*+G>P2<;-"Y\F4NHV+XX_38(.^5\;:<IF_A>ZB%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H(JF.#8>V$99R.YNC=H2>S#N>(^:$\$4H
MK%RAX/'+$NK)`XV'/4)<)<>^18^2%+G"V?Y80N&5K7H7712;V);H:K?QK6:4
M>U5$!'\KLW;2NPR7D]"3@^"_DV(-I^9**J<Y$.U@RJ<_"2QAQ,;8>6"V/Y5H
MU<3UZIH@[>*%9E=F<2J^;CA#8I/*W'7=<)R2O,&5RU@;"<Y/M4F='%0)4:V'
M(Y9AK;4/K22*#?'/E\>-Q;5)B8^%QJ(4"@4"@4"@4"@AF4]C=?8-+"FYHG&(
MHF`!"Q&RRD:1F@S,\L!+6N#8$%PJZ>,8%,<:U@L`\<LQ<LK8X6RO>UKBIGLJ
MZ'XFNL[FMB'"A"=]F38F%Q2]M>-=9DD%O#A7POD$/:2LF>CQ*6*F+\&.`PZ^
M$#?++'ARM;*U[EJ7YPV4W=?F>%HJ\/949R8=RS#).3:S8N,(KP+X\I8+$^?9
MT*%-EG<&7#O;++(`4(J8SQQMQ;<&5LJ%1WE^<XV\3%_\2[JV?UHU_(6SQRR3
M(*UZ<LIN;+#+AXX-W]-LBEVY^;_^#G9FXWRO]-\;?P5,K_CP^N?A\)+PL-[>
M=KMU)Z"/VRR5D)5GM1A)E*`@F5A,P\V=JLD0,EY)N`MN$,J/<P%CP6X>-?&U
M[*+XB$CQMX?VDL1J&*VQ-6X43G-CGB+=Z*S%1G>_A1<<+!\L8?SQ+K[S-#98
MXVXV8A[++.]N'*][_352YY6XR*%<RN1',L7S)9E[E,B>0(>17(KD'R.1;(O?
M&X.1?(&_$OA>W%OC]'!P41336GP]=1=0Y#EN4=?X>0&$\)E4\#KD/$<<A0$-
M+L&4%&9[#)C<8!E,HXL%LE$9,(V#+YG!,;<'-RQ(`J69F>LKIT0H%`H%`H-`
M_P#6C_Q^/\G6I^6^W\O_U?9EOSLB\M2M59-G=@QYG)CI:&#<+)Z"+@O9HR4$
MXW0CMQ0>KK\UD5Q.*S08B>J"JRE8F3%&S*E,L+7"ME<8,L1<TTER5X]DI13"
M.NS_`%:(]<W&X)'84B/QR*"#/2LOLM^%HZ>;-9^#9B8TQ&0\E%KOYU`NO(^*
MG/(-(L@W(F"AN]S&&&(DMJ/6YE>R#/$TDN7=KFI&9R$&BBZ\2O.VS^M<52(0
MD(XL2/E)&J;*-/1X.!W-H%OXM,-BO(!!52R-FGJADUB*4XP]K!W"S'6D^M1U
MRC.9O&$>4-2G,*ZIP,VUG4B')SE/5E9?I!_J0<P*,XQ-KDM[%N`T49OFJ.UP
MF)F00Q$?&]U+(_B/?G5\;VM<K2R/6ZSE9KP_=Z94VE=<DQS-\2LB*WRU8HUW
MGQL!QZ^5E]H2S&&RC77'2UT]6-K37;0Z:]&>$CXE%7$/$4F.8&OD5RR"PX^8
MF*S'1C>\NQ,)$)ET*13DD-TNJQ_OF$=>9$08Q89O%26J.VB":'4+6+WQPP`6
M%8L7RXM\OS@V/_)]-"(G/PN;VQ]8/OH9OUDY]CJI4G;'U@^^AF_63GV.A4G;
M'U@^^AF_63GV.A4G;'U@^^AF_63GV.A4G;'U@^^AF_63GV.A4G;'U@^^AF_6
M3GV.A4G;'U@^^AF_63GV.A4G;'U@^^AF_63GV.A4G;'U@^^AF_63GV.A4G;'
MU@^^AF_63GV.A4G;'U@^^AF_63GV.A4G;'U@^^AF_63GV.A4G;'U@^^AF_63
MGV.A4G;'U@^^AF_63GV.A4G;'U@^^AF_63GV.A4G;'U@^^AF_63GV.A4G;'U
M@^^AF_63GV.A4G;'U@^^AF_63GV.A4G;'U@^^AF_63GV.A4G;'U@^^AF_63G
MV.A4N+GMUJH(<`4<Y=8F:@5+&R14_G<?(X6)GQ20Y\H`:N0N."6.CII;,8/'
M*V`F9<.^5KWPQX!4N5VQ]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9
MOUDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)
MVQ]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9O
MUDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)V
MQ]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9OU
MDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)VQ
M]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9OUDY]CH5)VQ]8/OH9OUD
MY]CH5*%YQ?WAX;*-/!DSHN1))"`6,V4$G%>#/8K#95L;AW"76:YT\`DYV4XP
M+A8\DHI)PD>"X/R!<:F%B/:.BG/MZD#4[\N"MG&;NK!Y'\H.#]@7L80-D6HG
MV_*S)1KLF>31422@0!!L[ET]^%0CW(AX`Y.#Z+7H5?6*6NASQ5-*Y>))I8Q)
M^41R$="'S,PS-:2;C^5R/-,!LS1@NVS=C19T(F&)86^"LAFE1(&Y(2V!K+((
M3'!9]99<W?$PT1=DB.Z*6[LO'2J^V,2)'G(B%C2C>Y0,V9-DQ@"QW).Q(*AQ
M&-%;!*0)4081,%'!#-6"S&#QRMI]9X2EVQ]8/OH9OUDY]CH5*+G%XFWA]-$^
M<271N%`;>5T_'*YU(69!14Y7+<2V5[X"I1H<)0L+?BWM;#D^-E?Z+6O>EP?6
M>$)/_P`8[3MHBA$VD5GR:E$>]L2Q>*]?Y)\D&KY<-PQ"S\D='CJ-!B@V%N-B
M9Q6KEKVX/SG#>UJEK]91F'XH$PO^_)1UKW#\4D3@5A"3EVGVD;Z,;)`YXYB!
MCG8_UZ9,^&S!C,+B\!3-:(B6$RX@N8/!E>RSZ\R_RTSSZ^Q0C#Y\376J%"/&
MOB(W];-;,EQ7P!RX.'+S_P!AW?)B89-AVO>V&=FF`%PVM?(+*W#C3RM1_P#+
M_!8HT7=H?)SKO'LIL8#GGB,82I'V@DEGM$R8QQSM<0S'T``PLP3>'YR]K!CI
M@N&.-[XVMQ<LK9$SVB$UQ>F^%#"QBY^+&;JXRUG/,04PY4F/6_YW'11L[BBC
M*3P-(!ET*8PHM[Y99F#8N5\KWO>_#>]Z8/\`*5H>V/K!]]#-^LG/L=5*D[8^
ML'WT,WZR<^QT*D[8^L'WT,WZR<^QT*D[8^L'WT,WZR<^QT*D[8^L'WT,WZR<
M^QT*D[8^L'WT,WZR<^QT*D[8^L'WT,WZR<^QT*D[8^L'WT,WZR<^QT*D[8^L
M'WT,WZR<^QT*D[8^L'WT,WZR<^QT*D[8^L'WT,WZR<^QT*D[8^L'WT,WZR<^
MQT*D[8^L'WT,WZR<^QT*EHV[1,)=I3RI[2&[Y/\`QR?/[G?+&.2\S?PFO,[S
MAX>;\/D_SG_B7#P<;EOHX.#Z:C=8\/_6]N&TNN:!M/#BY$:^\'_'W/U!%7D1
MZQDXK-IW-MR-I1!5450)FQR2HF'B5S0/)&R1TH:*&RHF8>8?#?'/$L34VU:)
M/@(:U)C!;[7)S1L8VW*H,A]Q_.3R9SG8B8;GEHRHXD!X2`U74F*<<JZ0WV\:
M<3;*V3\$4!.,EB0?)CBFAOXQ:4OVGA-B3X/.OS8E)?DUBRWLI'=A#LTN>-&B
MRI#;Z:@01)NP[/"8DMRI$YP\R51R$'>NMLH%@4LJ'E0BGF,AQ@R^5Q<+`J/M
M+\*?@WZU.623[W?,@S](367AE%R.^'GB^4$_&[VE=>@^^OSIF=T!$F<G.DY(
M3M8F8@JCF"I@$!U07(>Q;`+@+V4?:5@=--"(ZTQ,/E8;TC2W+[O?2!&;$,/6
M9UMMKCB1(PA9!.->*8Y0LVPU6DG%$-KHAX3EA<B^9M2."9&#(N>7$Q#J3-NL
MW:_2EX;7]OPA_<ZW%J<+'[?"_E5DH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!0;Q'-/S>XNM3U8S$!CI!GE-
M3_*T(RF]&ODIK4<N\B:*J`9QF.Y-,$W-'2RLX$N9V62&8PA'$:XURQGB6#N6
M)J7@BT7TC\1I<\0NT5Q):0($V0AYU&%26986[&[`Q$F'AQRZRZ74I"7-I[R(
MN\D9&L0)6$-EG8$8_(N*3$&,89=9F*OL]XA/PTH7<`1`:>I,V=V;52P`5Q_;
M!LC+WF8,>R"PQ4#)>*6,ZV;&!<LH9VOQBXB48PY+BX97SMC:]:<KE8^*=3-7
M8*Q+^QG76$HO&+9!9AGV-&#-;:MF,#;*P1DRL):.753AO"V5_P`\,-F+]/\`
MSJ%S/=8.B%`H%`H%`H%`H%`H%`H%`H%`H%!H'_K1_P"/Q_DZU/RWV_E__]?W
M\4"@4"@4%`]VOTI>&U_;\(?W.MQ:G#4?M\+^562@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@XN!(F$;,'PB
MA4,^<!*EC9W``+`V:+DLC.9(`P9QPL,."4S.C7"QRROB'<7.^-K<;+A#E4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@T#_UH_P#'X_R=:GY;[?R__]#VV;7;.QYI
M[!SKGF3BCD5&TV3;;2`4-GIQ=5<[A<+P<:6U&R@HI0Z>2T_G:FN+``=Q#)DN
M7!#XV>>=K8_26(N:A0@?QJM9RK5B]5SBG:!3?,AICE65F'&W$82U)\9HC2<R
M(S%AR/!#S<J>75&R;<[@*E4LT@#K0BM<3A+`YWQSQPEK]9Y3Q'7B8:^R=L]E
MJTWT&6RCB./*6XT:<F+C)*)D0/R4('0R#CF&-VFX<G`*Y1'8P$@]<4[@>1R)
M7.Y<?$`<7(.]JJ5-6QQ[>*YJW'4[NZ$7H6E)`36&ONADNN>#C,*V@-(D=F1*
M9FYR1J,[\%[-QB/).CTF(:Y'!&R*BBX\B&/D)>V-UGUFK2II_OI$.Z`CX3V"
MU9:CQS,)'CMVJ;.F9FE68Y%./9>1#KBBV2&\"G+KD355G/A'3AQBN=C6!TOR
M?$-EBV>8>.8F*8[NU^E+PVO[?A#^YUN+4X6/V^%_*K)0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*#0/_`%H_\?C_`"=:GY;[?R__T?9AOOK\_MGM
M8'[#L;+D?I+F7C#<40TZ5H^;LE1R\B+=7B"Z<9#L07$0/^32+CP(6#!5T_D%
M9&.8@G"8P0P..5%B:FVA''P`)M5HBCA)6I1@EQO8W%,DQ$YF_+36?S_;&MC1
MD=^MR0411UA5A70HK5I#B@<DJ$R!I1,`DAO+)G+"X>/TB2FOM%KG,#PN=JXD
MF8DZV!L1%1Q@PY*NW&Q&NPCY:3S<+\.S%M=&QIBG4Z:^;K!!'5F4Q#R\J'@3
M*</Y44LS'`-<+C7XBD^T<,6??@]3O+SJ?K*D>>XT)ZW2W+T@;42&09;.<Y23
M^TA+>JBEKD_@F_9453#7#C3%65S*V0L8$S4@BXMR7Y&5\C5U+]M97$\/+1Z:
M-9G=)<F;!2'&CX?+HB37#7YJ%8G0G,BMU,C/6IHJ[705U<S=1L<Z<>KV$5[F
MU$(##`D3$!XA?++#/BADF;Q#J-Y=;]>%"9="EL_`L+G5J0]\PB3_`%<W%S',
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M#^5O)G%YEY2_C7)\O^74:O\`Z?_2]_%`H%`H%!0/=K]*7AM?V_"']SK<6IPU
M'[?"_E5DH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!H'_K1_X_'^
M3K4_+?;^7__3]W4GRG'$*,1Q2?+;V;<=QZTR@9UQN]VJI5&0DD`<R`1*V,G3
M>88=S!X^:"+EP<>,,9,"X!!8YB9XXW'5$A7<W5`Y#38V&!V&B7"$GDL$&XV9
M*-/-'(MA6<RD,8+%FL`<.F2^0;JL9*#!BI@F.!\N(`+B*%AD$);$M3TK+)$+
M9[7-SS`NZ^MR<HJ7)Q;()L=P1,E/ENGG\DX)X)<PHXG6P7/B*H(R<`;#S,AW
M#Y0OAE:XF.-N&A4]:PXYO:G6DA,1G7P]/<1$IQ))PRL<B<V_VR6?I0@6;^3L
M,#F6T,HX*8&0#4PNJYX9AV$Q3;7-7QL!;E*%35UAV4*;(P!LBE+BW`,RQO,2
M2V5,)&<)^.G<BNLNBJ9@M8V6**6:0;,\TS-EKWS!OGP8C8XY<2^7%RX!,3'5
M6[=K]*7AM?V_"']SK<6IPL?M\+^562@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4&@?\`K1_X_'^3K4_+?;^7_]3UV>*5$CJFW2R36(S8I7YD71%-
MC.,NT&9(Q&+9!*XM!Y(KFN[(Z="L1/H@CV9HJ7@I$D\YCB"I\WR+6O<40/#-
M*^N)ZO/6X/#$\2*==&&)908\3`+S1<(SICB`UIO1Y&,FJ2F[9HBAP8S](!^/
ME=E1$9G.T6-@VGJII9''51$(TI`9\HLGN-C*;N+6YB_5C>2)-LTM]Y:GE'\-
M!FT7B,[<Y2@BR1&#21]BPMJ8L';L91FT3ZPY0EEKN0TXU3`%5Q7$DHEIH*,7
M$Q'OC;#E"3,5U1--V@6\<Z/:98^`UWQC\_,^QDP;=EMCE"18W4DYC(DM:-J\
M)IT`FU-MN,J[E%>8\HK%D^]RJ9F1&!!N>#,7+97'$$3$1U;"_"FU^V#CV2)=
ME.9(,5M<TA4UHTAUY2V*MN-A+JB['AK7&KC:KV>V`<<N%?1PVR`;5@B:(8-9
MX'#1/++*X1?'&X=T),Q5+-;5:8`39(.NJIA(FR*<22=D560'&H,>9G0A81X2
M"U[V"2TY;:^%AQP&D#FZUY.2<<R0>(F)=2S+XWQ#&SJI$U;(/P_T3O:[]_%K
M(-"]'X?Z)WM=^_BUD&A>C\/]$[VN_?Q:R#0O1^'^B=[7?OXM9!H7H_#_`$3O
M:[]_%K(-"]'X?Z)WM=^_BUD&A>C\/]$[VN_?Q:R#0O1^'^B=[7?OXM9!H7H_
M#_1.]KOW\6L@T+T?A_HG>UW[^+60:%Z/P_T3O:[]_%K(-"]'X?Z)WM=^_BUD
M&A>C\/\`1.]KOW\6L@T+TC-WZ(N$H_(E(-K:7?LTSU99=@,CG>U6_1O)B649
M:P=;HO.,Q,<R?.72"6"XV..5\^/Q;\%K\-"]),_#_1.]KOW\6L@T+T?A_HG>
MUW[^+60:%Z/P_P!$[VN_?Q:R#0O1^'^B=[7?OXM9!H7H_#_1.]KOW\6L@T+T
M?A_HG>UW[^+60:%Z/P_T3O:[]_%K(-"]'X?Z)WM=^_BUD&A>C\/]$[VN_?Q:
MR#0O1^'^B=[7?OXM9!H7H_#_`$3O:[]_%K(-"]'X?Z)WM=^_BUD&A>C\/]$[
MVN_?Q:R#0O2,U71%P!3&Q$=/VFW[$C$_&DLJ3O5.U6_<^9OM)=,+%8Y3^?7$
ML,7\I-]:=(G)8XWQ&YIQLKVN%C;(7J$F?A_HG>UW[^+60:%Z/P_T3O:[]_%K
M(-"]'X?Z)WM=^_BUD&A>C\/]$[VN_?Q:R#0O1^'^B=[7?OXM9!H7H_#_`$3O
M:[]_%K(-"]'X?Z)WM=^_BUD&A>C\/]$[VN_?Q:R#0O1^'^B=[7?OXM9!H7H_
M#_1.]KOW\6L@T+T?A_HG>UW[^+60:%Z/P_T3O:[]_%K(-"]'X?Z)WM=^_BUD
M&A>D9I6B+@%F-]HZAM-OV'&)"-(F4F@J=JM^X<\?:LZ9I*R,G\^L)<8QY-;Z
M*UA.2RQMB#SOC8WO<7*V(O4),_#_`$3O:[]_%K(-"]'X?Z)WM=^_BUD&A>C\
M/]$[VN_?Q:R#0O1^'^B=[7?OXM9!H7H_#_1.]KOW\6L@T+T?A_HG>UW[^+60
M:%Z/P_T3O:[]_%K(-"]'X?Z)WM=^_BUD&A>C\/\`1.]KOW\6L@T+T?A_HG>U
MW[^+60:%Z/P_T3O:[]_%K(-"]'X?Z)WM=^_BUD&A>C\/]$[VN_?Q:R#0O2,V
M[HBX3$GR6EK>TN_8#`34:/1F(H]JM^A>4%10!=%WH%SO$3(0US$4JGVXN6.-
M@N4^CAXU^`7I)GX?Z)WM=^_BUD&A>C\/]$[VN_?Q:R#0O1^'^B=[7?OXM9!H
M7H_#_1.]KOW\6L@T+T?A_HG>UW[^+60:%Z/P_P!$[VN_?Q:R#0O1^'^B=[7?
MOXM9!H7H_#_1.]KOW\6L@T+T?A_HG>UW[^+60:%Z/P_T3O:[]_%K(-"]'X?Z
M)WM=^_BUD&A>C\/]$[VN_?Q:R#0O1^'^B=[7?OXM9!H7I1/\+43VU\^]K.Z7
MFYV[/:5YS]H-R<_\@?A^>;GM=\J<ESGSI]JG_J?Y9X.?^3?Y/XW(?E5*7[?]
M/__5]_%`H%`H%`H,&DJ3(_AQBN63I4>"`P8^9R?Y4<[N="B`E(:,2N."4"%.
M'3&6.&.9DX9"`!#QXP@XXN`0>.0F>.-PC;7?:O7?;%LJSOUWE=L2BAM]5Q1'
M!FAYGBJFWU40'G(!)?;RT32W"B"FR_"(!<T5"Q,88Y9!WRMCE>Q9B8ZK!41B
M;3?K%?V#A%8KT:;T#:+L7F$ZQ&FXT=QX-A]-8QB4<[+<.:.<.8HKL;AO/$(^
MG&>2.$Q+VQ%#PO?@H,LH,&"DMACR4?AT)SI@DG)C&29+4&9CF)Y9*L-=7UIK
MI#G%#Y/D;)A]P-T\4#RMG?*XI;.U[6M:U[C;.:#&W>\6JP&TLO%[N%':C5;J
M<=5UM?73Y=-2TQ-3BHQXZ;-&S.88081<H7S$R^GAXN-^"UZ"`7+NSJ,S"\,F
MGCL9$33!V&1$)RPM=S/1'01)";CG(%5)O+Z(`JF"@]D18+'@,0#0^((&8XP8
M-LN6SQ#N6IX3\\7DTH]:R^^'XYD%F,QJI9M<<SK="L10F\@(Y`+(<ZIK"PI#
MEB">1*A8WRS%%$QPQM_#>B*MF/$-T9*1<WYJ-;8027BMTNH9C(+U'D1OA)!]
MX%<28R@V[<<YB:+K"234"YHZ",&'F2)#AF1[!E\\1+EJ>&<B;A:K!2PGP7GL
M-#]I>56V$[TY@6?K=R<)QM&$`-V%58`MB>OAD7.-,7%5`MQN..E_QL/'(O:X
MEA4]:P[>"]H===FR+E4M?)JC>8R;.4P4AU"Q^ZDIQY(!XW8UDGXJ@)`P(.4+
M*N)$?(D8RQL7.X@"7`S$L'G?$3$QUA/%$*"F[*\0G2:1)A,:_L[9>+%F9RZ\
MO-;*.L5^Q%QCN9LF311=;Q$NI`$PE%;3QR`]LBI?,4?*P(F6&.6.&5[%J>M+
MD40H%!@S<DMANYVR&Q&TYTQ8=\3*;>1I'0">8F1]HJCK;":\VZ25L,P\,`QE
M=K+!4\%;#+.UP!L;WX+_`$4&<T$+SAL9!&M+8(/.?Y:8<0M=662S=25E^.(@
M@%55<-ABCA):98X+@,H';%2X@XF`..=PBX0@V?%"PSSL6(F>C[`;!P>;=48L
MDA*K&5'7,Z&JN>*D1(<!!6-OMMHJ`3=*DOMZZ:*:!.(P#=4`#F)GC6!%`%QR
M#RRM>U$IW<LR_%L$,1:D^97^U8SCYNXEKK+N>2R30T0D(=,A$B!7(V=$#Q&/
M*)T?``L7#XXY@;/$,/#+/*V-Q5]$)J>^6ER,FQ(L*FT<'$4F>!A@(@4QY%;>
M)!^Y%CUTHV(AF['K@9EB:S;F(XPN08()^]BV>6(][!W+4\.VONKJ+@]Y0C<7
M96%`'U"B&KN666R9D5L%5*/T%NWPQ<JHYL#"B$$FEFN*)@&JWRRX4P43#`U8
M+//'&XJ>$@0I/L*['LS&0X'D]ERPRO*)E'$<3(7":X0*+!(,N.;2%"Y43(5.
M5"X!L(3,N8Q#&Q#%PSOCQ<\;W),3'5+M!Q#YXHED3JF?&Q+$4XH9/'3&6.>6
M(!0H#F8,C98AXYB98A`AWRO;&U[WX/HM>]!2Z`O$>TDV@>Q..(-V!:SV?*FC
M'7"C-G))=S74U]&3,<LU(\VPGDW6]@X\$X$/(0?$CD8S!!PR$SQMACEE8M3'
M9=RB%`H(RC&9(TF4%]&(S=91U@QI)KTAM\YE"BF4LWY+CP\&F/-J&+*9$CD8
M-H1X7$,08"PI42]^$,7.WTT$FT%:-@-Q]7]5C;1(["S6RHI./H8P&V"KG.F,
M!SY<F9(DCRL9#)%3F20W$XVIEPC*H=YNG%A!L,11\+Y6M18B9Z0S=&G^%W%+
MRO`C?DAL+LOH#("D9>8J,>\IJJ(S1UL-N`+"N,2#'3DVXRP+B%@6&'P-Y8Y6
M$L%R=[9T2N[H]A-H]?M4FJE/78:4FW%S;75L)N(AU>R/&#*PLBEQCF1)*24@
MFI+"CD5)%A!S.8)?,,J7PR%&RP#M?*BQ$ST8'AOIIL-)$71&6V-B\[(,TH+;
M<L7H*>X`U#!W)#S*#'F8*162(9A!+&WD3+YB(Y0R:`-JF./\5"%^BA4\,-3_
M`!-="%9MR>[DS:2+SS>ATVEDGZHEE$^+8D,NK`[?0LT`KBG7.OHHN+I40F2,
M(0:D`;,X7#"SSS^BEGUGA:"(9BB^?(\;TKPV]T&1(Z=01P1!=C<-7-)A^Z<H
M&DE2+_EX!&"IY,52(Q8T7&##'+&`<PQ,,<\;XV)TZI*H,0D!_,V*V2ZI(D-P
MI[38S(0U%RNQS*N>8::A(*27S-J*H>S"#%$P+%"X>6>=\<<K\%OX*"#]?-T]
M4=K33@3]=9[CB6U1JERYQPH[470C"VDD#8E@"ZD:136!55LEBF+V"L:Q!N7Y
M:]@[Y\>_%HLQ,=86?HA0*"/8IE>.IQCYM2K$KN27W';P+&CC9=J&(**DK)4D
MHG$DT.3$&"`%RP`44\8'+APM^6'>AT2%00`_=K-:XME-E0A(\YQ>R)<D;$CD
MR(\<[Q1D=TN2RL?'24;R>EG#00^62XK%1"A"V?$N>-X9`@<H+:^%%J>M,Z:4
MNQB_7:_F(RGTV74[HL&;Q:14%!5"ZF=9IMUD#*HWB:]8KD($1.JB<3$'#!RR
MY6P=K998XVRQX2,(FW:?6_6P9HEY^G",H>&?IXRG,\.0G<CMC)?,$<R>"@(1
M\IF0.$BF9J)>QHUEQ2Q7EP^5$PX^/"6(F>D.M#V_U8$E9SP;;82(<9<9;<.N
MUV,$5^-X!P-YNIB3@OJJHJEQCP890%(;^=E`YCEG80H0OSD;'`'\NA4]:=8U
M-U]2GU$+[GQF[#14YX<C#,^%(4A(CL3E!OL\9."`''+KHY<3,8B9%!-`YEPL
M@^4-XC!W`L)83#C"IZ5E85L.5!>C:;SQ:RH66VP[$-)<K<6B6661-705T@75
M$A4*99XX9Y%CZ>:#%#O>UKWPSMPVM1'>4$9S#,<80!'+BER9GHC1Y&S2\D><
MCP<`HP*0C^7EU,;*/SL0`$P+CY07EDJ5#X,+\(H^-K\%OIL.O1B$`;1Z\;4-
MY7=6N\P,:74)OJ>",O'&:LA*`J&IB@<Y+E%@AE8%13,S9>U\P+CA88CX8Y7#
MOE;'+@+,3'5/=$*#&7H\FO'3.=D@O=:)-MEL5LKSR=[B4<L\$]`:[82S2VOK
M1_,/`03`DE)1$4<6^..5[8!WX+7O]%!RFPY4%Z-IO/%K*A9;;#L0TERMQ:)9
M99$U=!72!=42%0IEGCAGD6/IYH,4.][6O?#.W#:U!WE!7P;;#6<";\M:QIWB
MP*?,".:B)$F;S1,7R$7#1\W%F&,AW-\Z!/8-W"ZC<KE:QFR?_&>3Y"]A*+4U
M=89S&LQQ;,83S,18_&V_BT>/I7C)Z&VPHA*A-OOY!3D=56FL=-E^,6R5$P@X
M"8@V(>>>.'+XXWOQK96L1A;]VJULBR463"<CSI%K(EN1^9>8\=N9YHB0ZW'Y
M4/"I2/S!(.&PC/\`+JL`(43^4MAS\V'D`7Y47'+"Q:GK3%2.\FG*D?E]+([.
MP>8/P$4.GYE+X2.V+91V135`)'4SKCRS4,0RI1,7!PT\R)C?/`NHB8%!+XF<
M\0KBIX8^K^(;HR@,2/Y/7-L()1X_E3)S81V[5.1&^21G<.RS*:2=Y1'-&#8=
MASS7.+)0)0`O;$8H(8#Q%QQRRM:A4\+@%#98^5+'B0X1HF=+@FRAD#.P@)@L
M8#Q&`'!$QX<<PA@L[98WM]%[7HCD4'__UO?Q0*!0*!0*"D?B.PXXY^TKG.)F
MC%Q::'(YTEJF$>-!Y`SBPPY3;8D!I.VUD-_\%RK;=B0&@Y'T84W_`">(K%2P
M1R]BH@UZ+$U,2\W4@:*^)U(35D!4NP)P6(@6ISA);6&=+*[K4:W:F1F,F-I*
M;9L_,$B0^^XF(S0U8]<*NDA)"8Y71@=OCGD:*@@!@Y\K&[CS_P`(;RU?WF<T
M@N_6T!ISM)>U<7ZX::Y1S)0FR9!N$]37H=DUWK2>^'\&2D0FB/0PE12D9HHQ
MY+`7A`LR-PPP\\C88E1;BK[)-F_PO-Z"QJ6&[&\*2E[)1]UMTY"+-AER^SS1
M]\M>6RJ#CJ_)Z837IZ9X)KS))E#Q0Z:5C@:RAFE'$YF14<\3&(-I(]H[RL"1
M\*_<=ZOICN6=D24I`5@]K=.4M_/`SLSF0$6-24C5$9F;39CDF_+J1RGG%*I,
MF46LBQ,!R+U\<C!8+,H*+>E'VCLAV0O#=WM\V8P!,:TR\_)10-(VO`L62DW=
MKV8U#L`STV]Q)\?S+=[Q/$9>!6W6WV7#KL2APC002L7+!CX$`L<1LA\B2B/:
M,Y[N0?\`#I\586;-LG*=SE1QO9X-O<4`"4D*7&8U(_FI%DZ.51%@1J(P:C+H
M2LDF$1WF21HFDF4!NIS3$3.4LH"XBA879+]<-\*EHVS2OAIN354M%"<_',;@
MEXJ!!I2FMEY4.&MD7(R%A4%<]W9)ZVY$\JZLY55Q3952Q/`DTTP)QR@A<###
MB5B\VT_;$^'_`+H*<80I'[7UR!D!8D7P?]7-!72H^?T>EB>N<UQ;*#2?CR<+
MU'/.T(JI-`HG8B9A*+;Q6QQE)#"Q!M</,+,6-1,9SW;AI4=DD;*Z;;<M(KJ8
M3F%XLY^2=!;"B"2'LUP6AL69B]U)**@22IK^*RQD%(::PO%,U$\EW5"QHH*E
MF4_(Q@<QOAA68Q,9:20M(]XT=':4[O/2MTR5.;H4-\",]LA2?^L&)18?.V>O
M47QHPWY'#:9\EY,)KQ"S##$NWSI0VJ&7!S(4<YF&)R]K!1NXZ7AUK%\-#=*-
MB\:Z^.?7+VU(+5G?7C9YT3->1XS2V>]&7#^BAN#GCJ\:R/KR6]2)U>>UO-M,
M'%*Y)HB<8Q.&1`P+"C4)F.MMGGA)Z^;'QF[Y]E':K6D6`9/D%MQ$R$!/:KJ@
M\U";9BB(R+@;<<1)%32BE_/UT%B[&;PX//%AS&A#BA80`,&^-BXMQ$,^TQB(
MG#=O59*#RT9:.[]O]*;&N.&N(4-I+,\4*2MWT'<)>EV%5P@@L^S]>KQ:A1G,
M1I.5V244=3HLIDL,<C!`($OP6Q-A6QX]@XW<=;[*HQ#X<WB@M9B2&"Y&7.2B
M@GCD)=I:'!IV:2(:VW+M.:@W1+6$>/0E-SD4/++CC[(T7$63YALXJA,YS+`E
M<8+@%+,Q,LJF[P[O$6>ZM"9M@Q1/,9QBCL)>1H4C!&VB;\@N_55\BSTK.M)7
M72]7-,#2";^*I'?DX8,XD9O&Z,4)V1;@B96#$IDOUSRFF3/"DVDD:370]G0Q
M9$<1Q^2#XL2T]58OLEBCIZJCNP$FN>'N$10"4N)9)';PC[N.ID4PJ4`!2C=[
M9+@!</`/#%2?:H_\(\*>'OXA(DS(#R,0A*")L`XC?AG+3?V^SV39)MGQ6IP7
MJ_";$VUSD^/4*43BC(9M==;844X;EDU4P<N1:]P!,BO)B'2W%5>,HDB[PR?%
M,Q:<M-MPI<YI3B>!2+T&656\],Q.(R\Z2&U+3>3FDQG.G*<%9<4E1'B,!8'L
MMG0&^;R*GLDL)-&&X,J9+]6]C?S7QXH.O,.Q)K1K6X92:3);S^C,DKQ^_P!J
MX;)00WW'%JLRT%QQ$Z]@%!92UFSC#-"-UU&5`X:6,D!2'S+WR'O<<$S$YFY0
M9KMH!+45RYX/4EJ<'1LW'=K]K1.,8[>R`QLV$15RZN8A6-6%"2&[5G%5P=TH
MF4RR2HD0C!*ZN23A[F<P\P"I@/(1P3/^V>Z<MB7[L5M;X><;S'"&E:&^=C5]
MY,^1(TAN47VPCB)$;E:CK6[MR9Q5UP.:.V9(6"`GI82HA!@G.9*`BF3,6Q-$
M\!.4$5$U,X:7%[PT=QD=CK+2:&HS\55'8C3E<UC=:I(<LZYG5&.9P6MP<]A7
M3/;XQ8[P/M)`CU?).$8XE)[7Q4E!.S1`"@N&0]PS.:FOM'*037A_[FIBP`QU
M;2Q'V&3]>UOQ%'=BYI#DB,TEF[C'-L7<R5*&BZB/C(3<<@!M%-I^:RY"ZM9)
MP"#2K``&<3(@6(A+CEN$\*&'IZBJ-)F5]G8A=,93S,4O&9;E%56G1":NV7DZ
MEUNI".-C&S9A!TNQ'9+&:"4@%$TL743.2D<S#S-"Y7Y7B!(3VF,5T;5ZK+&W
MFG&UAGNM((!XBGE5MKJ<2"RSP"Q$-GDLT6+!Y""7Q##QS&%M:^65[6M_#?Z*
M#ROE/#I\266M>M3H*/1DT]5W!I'KWLDWVE,Q2<&NZGA*DBRQ%RW'K;:38$8)
M0PI1>W#@JQ?-6.F#0]^;VXP7`,&'PRF_M%S/*(XQ\)S=1EQLEDWAK,J2?#)6
M;VHZ9!T56]EXB;";*>"3";W80TFIAYE^28W:F22^5=,5+E#:\</K5R`1P8$F
M;Y4/)2_:+ZI21?"PWI+[J0!+RJR32<T&8/I\IM-Q-;91*72>MC2AUH(2;*<1
MF'-)Q%T3,[$E45\%/+R8BE#",Y<3N>!XZ6QOB)@H^T5*)0O`ZV3`@$N9+Q*2
M+[*%=.4)/+.`O-A(!1!W!:^W@SJ;+U#70GI@1Q<S<UW,9DR"QRG-B9?*Y0+/
M`;\FE'VSI);N\*S=Y:GZ?7)$$3)^OTBR!M#O_+25NV2GI'N,XH7GAL/]*BR(
MC,?ME<-/%`,J[D6R9\4QB0XB1:_.^/8[A<&RC[146ZS6+P=]G/,]F1W-T2+[
M3B!5VMUD>,RQ8?GF.S"<Z&)&<%[`LV4WJ42X?,$`4<DZ72^$4F:"!73:VZ2]
M^=J!0L*!EPJ)]H[2V5^+=JSLEL$TB<6:\Z]MQ[-UW0NMQE>56;([&BB8XX60
MW`C*"*T'^Y)`'L(^=3W"6)`FU]K).(RFH*R65&RX+`AVS2SZS$9F6>G(%E/6
M_<"8MV42)&*X&\W?"P+M1P`LL^WF"%+6SL=R"[9&64<P63T<\O)^+I;Z<G%0
MUXPDG+`%^1"X@N1>P%AUB(ONYN_*3N-/>N>O"[K#K2T?;4]$LLL/=QO)6C(K
M+&K#5D1@$B,FMV(7!*R:EA(LH.9'<!QMC*X9/"Y4H"8N*3XX@-@A%9MJX3O"
MTVP2G*5B9@:\E(VA.69'\.F3C\A+T[Q^]%[7!-TR9)MGO9KN4),Q1%^2'Z\3
MA.RJG'&X0!1\C2N/B)F2PXV."FOM'.7(A;0[Q!8\)L-QK&H,7*Q_6?56-M34
MALJLLQ4>>$OYH6R+AEA3V$UU=6)T=#B>6(Y21BRBR%%V#)1A'731DQD`+G?&
MP9)F.6Z#PJX!F#6G3ML1=-R,$VWD%(,ONXNW#+G0WTZD)N/R27&\$--D-^MD
ML5;KXD`,LL7R4U0EC<`R)GCP7X<;VLA/:8F<-C55E4+?Z+GU-NDNT\11BA^<
MTAR/!TA,]F-[RFCHWEEQKC?.$4M.\K.!024-.YT:%QQY8V9``PX>'//&WTTE
M8Q,2\_VQ.EOB2[*DE"2&MK@?U;=<7:1QCJZ`AEIRB17E38W`C-<7O%_I15R1
MB_\`!!0FF68C)/!%R:NN)PAT8W<MRN(1@3(*9:B?6._=%Z1X?>^2(P(N3Y!U
M^V#V`B)/4=G18SUY+[1M.%GA!KW?YB-,X3>J\K($P+:<BM=&/(:T:*EPUYV#
MMS$^+<;'C9\D(6XY=DK^'GXI1S87:=WFPI;5'0[V5M^59DCILZM;)E.]D21K
ML[F=`T19.!<DQ#7CBLW'LIDBI?`VT$,LF*1+!7$4@\,\<PQ<5"3HX\+W;J-Y
MRBZ1&VP9(3"K'GKPM7X"HC[,XJQ5.0RC"6"GB6J8R,IS*H!K'G`YTM&P6@1R
MQD=>P#MBD8&BUA,;*3[8KY5%C;PP_$O:>NYN,(D@V4M<I.2=6'DQIO7CFT#,
M56YLJY%S8-F/1ILUA)[6EQ=;K7.I<.$5U'N/G9"*!Y&Q"PYK#$S<P.RM^MW,
MKL:C>'#MC:2=-\)J:\U)6M<>3EMM*CFC]T3.AMHTQ22JSM?U;7T@LM:/9L=Z
MN<:AV7X^4%(FW2ZRX"J:,"+D>Q!`.YX#$F8S759KQ'-:]F9IV<CPM#FL=S:"
M)*&J<EF)[:SUBI%9KTPAN0QUMS-7;%"<XA*4U5$BU$PS.L\)N"V",&%0Q@)B
M<&XH!<D3%=4U$V6Y/#]D?Q)MDF%K*AF8RD)P:?GXICZ-%..H^#DE:&+`L"5U
M%)1D;$R.1=)-U/<4_D6-)@:FZ%#\R1P-FC0=\AUK+`/%Q@/9J>7+'[/@'4O"
M46@\XW=<<;!SPW'?`J)+Z-$K@<"2KJ,)Q07F^1&HD-PZ]#[?"'4G!DGJ.1(O
MF'8K:XN(P>23UF(ZRUGR-X86Z3V,2-`K,@4PP6Y[8]]-B&?-JI)$?G$)2:.S
M^J'LNC>!39M-=`[V,.Y+<`H+56C!DOY+Q2B-C=AC);B8YJ:^T=;9*N>&UX@.
MQC*V)<Q*.63KVV7PUM;DG+5Z9CZ&Z#DQN+5?5Y;BYMJ@BC$S^3VRWBPDE+@:
M@AAJRI@3$/M]'-J(.1(#(J(2XBLO1_IHRY4CC5#7>/9M`;)24F-$+&:#M(-#
M`;%#3#3<0B:012<!!5MQAG%-)2"9<LH&2YT8F;4`AQBO%+B!88UF>LTLO1&N
MWQ7(4EG8?0V9HE@UF9R%*+@7(.5FTS@W`UVL(MAL?8.*GZO@AKST66\V4_,L
MV6P<'M<T<!L)<+D\..+EAADE?7$Y:2ML=)/$4V1>D^;,$->5F#$B5I>U1(O3
M6-JRQ%CKE"48HA%CR@F.=YNE59,ELV/'0-9T/5,R*M\=U$QCQ4AERV>%RQ;E
MIEN)]8J+?*.=$O$`:KEUX!F*&YSGI4;L7Q"@0V^L=R$R.\-17`AS\_'F_/:*
MHMUWJ8SD/$XG5D@E<9.37/S\JGA)`)D>V&.6`N,U*OK;\-'Q70VQLLC&RLT9
MR6\4!"1GT[`9M92&VI]<`6X,7OP-U,YP')O-+(2FEQ(CJ9X!1-D6J.03^<(V
M((HYC'`PJ3[1CA8]Q^%+M*VQIYRBV+WUB57)!\4:+XY3%#8\LMHQS4N:=)'6
MW]9VIDBO28E%,!1U[:1Q#"AA'@L%<@H&+GU/D"N.)G!2?:,6K\H>&_XBMXB/
M-B*(-F:"XR3".G*7/<"*VR36DI<V->D8HSZ+3S(,?8`304;A9MJ@RF@B61Q'
M`WPEG%/##!Y#D;%BI;CO.6P_07P\ME6UL5KK(&UB3*ZA'D'ZCB!1\`[)V!4L
M67/_`&HYD<S9;SE:S%DY6\Z5%I0<]BP!;,[9:0BI,8,C8V..3PQ!),XFF2S!
MJCL1*/B21*XRNJ*:VX<8&R2O*KPD4)SQ`J:\2]&3FAU09CC?\@,(?$G-"EM$
M.:,`MTN&+<VA!)Q0N+<I<'`0X([D3'UZIKU38TC>'JC3TW"VM!0JT-C/%N5B
M41,J/%V/D!':>N\QM^*VFD2VCM9IB*Q<DV&*79Y\T:;N!8@IE4TD,8%!*E0L
MAK$G-9[(LWYUHV-FG=%CX,O3/SMU@4#,$NN>YE83Z@!M2Y+SDB-ZF'*QV(I*
MLG20DNIFQ/'0^81T_BB)%E=9%L(`$/Q.2SP+$Q77+6>K>&7O8O1TWXZ!UO#3
M#NI442"V1U\\^HT#*;I**GO^P-GD5!0#"8YA;@IRTPFD94<LW$FIP)=Q#<@(
M#C<7'(NI?M'+*I"T2W<6;25-39UEV4:,MS1L#N=+D$)\6[-02R,M>U&<E6"@
MV41V(9)L$XFN5LNL[%F2RK9(;M,DP0<,BIY/%%,8F,!$QTMZU&45<A%FM(D\
MCA)1=Y-LH)5U*"<"$73S[D+I14)<.$``2Q($`D:4\!<PL,`0<<<,K6MAC:W%
MM7-DU!__U_?Q0*!0*!0*!0*#B!D"(1PPHA$B@:@;"!`-'@RP.!PR"6X_-P3!
MK'"PXP1?E,N)CEE>V'&OP<'#>@Y=`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%!_]#W\4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@__]'W\4"@4"@4"@4"@4"@4%.V),VSTGM)%?S+@B!O-)T%Q5)NY.C9
MZ045Q")&1H<$D,M)"3J4YDU,41@0;9B@`*)T(++*^.(PEK<:Y66^=6XOW$ZT
M?%C*7R74,'G5N+]Q.M'Q8RE\EU#!YU;B_<3K1\6,I?)=0P>=6XOW$ZT?%C*7
MR74,'G5N+]Q.M'Q8RE\EU##J%:2MID#-)#78DU11<U]8+-Y"P5MQ)%3LUI?.
M@F3)-#2<3FF@-U%8-ER0P@18'CC"8!9Y8XWMCE>P=OYU;B_<3K1\6,I?)=0P
M>=6XOW$ZT?%C*7R74,.F5Y,VD0.;^7HFU/1.=\KS7RON+(B;SGD.2Y?F_/--
M0>6Y'EL./Q>'B\?'A_AM0P^*A*NSB2&3&5(MU)30E$'G*>*H;E2"3#/%^*'E
MRY/,QIN'B:!XHN-^-A?+'@RM]/TVH.Q!?NV1@8N7`AG5H<P;(^5"H`.WDE"#
M&4WC@A^42X6&F668Q'CF`[<MC:X?#GC;A^FW",/EA(FU@H!$T%#^JHA93,\R
M33&&X$CY@*!S\_?FA$;'3.X9LSP%1?S8=\L_S>7T?DWX`[/SJW%^XG6CXL92
M^2ZA@\ZMQ?N)UH^+&4ODNH8/.K<7[B=:/BQE+Y+J&#SJW%^XG6CXL92^2ZA@
M\ZMQ?N)UH^+&4ODNH8/.K<7[B=:/BQE+Y+J&#SJW%^XG6CXL92^2ZA@\ZMQ?
MN)UH^+&4ODNH8/.K<7[B=:/BQE+Y+J&'S'>&WY8$8R9@[60N7+A"#CCC[:R>
M$"`"%A<0488432_'`,(/#&]\LKWM:UK<-Z&%<0=]!C(P1<N]?#6,&#`H8(``
M/B29BC##"YV#""""#U6RS$%$SRM;'&UKWO>_!:A7RLEYU;B_<3K1\6,I?)=0
MP>=6XOW$ZT?%C*7R74,.,<>^W*<5&/*$*:OD"1;"XA@X<VYDTJ5+AVO:UQ!C
M`^F.`06%KW_ARO:U##I@Y9V8&3C"N%&.HPJ24&P+&E0/<Q_YIQ8P)Q.3`,'<
M=-[E@1A.5QXN.65LK\:W!;Z;4'Q*S%L@>$N$2CC4`X+;DN$,KNB_#`EN7,@$
MP>'`+3G/*W+&S(86/_2$$QQM^5E:UP[WSYVWN>NEVA75WRGB4Q/Y)W:ZDSGU
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MI?)=0P>=6XOW$ZT?%C*7R74,.,;>^W)`+$8]"FKY(',8`M@*;VYDPN%D8-"X
M`%@,1!M,<,<AC`XF.&&-K\;//*UK6O>]!Q3TB;6)G+W4H?U53[%2V!TU<]N!
M(Y3FQ,4?FH1L?E],P^1+"&?S>(F7!A<3\FU^'Z*#X%Y/VB-IHJR5BC4XRD`"
M\@.JE]QI#&301KY!8<B*>#TUR*AB\<?"W%OE:_#GC;_EM0=UYU;B_<3K1\6,
MI?)=0P>=6XOW$ZT?%C*7R74,'G5N+]Q.M'Q8RE\EU#!YU;B_<3K1\6,I?)=0
MPS6$9+790:BPJ.AK)+.<[9?CZC]PH:`ZCCU00U5D.,Z@CG$9S*+38R@IIZA@
M5Q&PN.DDA`[YWPOA?BVSR$IBHA0*!0*!0*!0*!0*!0*!0*#_TO?Q0*!0*!0*
M!0*!0*!05HTY_HP0M_\`HPK_`/:SE%GK*R]$*!0:BMLX+\7]\3>Y''J/NO#,
M,0:;3VX$VH_>,9,YRKR4HE$,B6<9DTKJ\'O8\.&J+H8Y@+')1%L&&);'''"U
MK86N%PK;V7O]0K_[RK7'W*1W\L5,&.&D[Q5='O&_=4AZW'9>D]3VZR'=)9NQ
M(M:_I)9HI,5R2<4,#Q(ZX$9K,F,R#353>)+`R$[30-@2P)2X8QXOB`%CEF73
MUGUJ6YAN:K?ZB`HWT0J>\2?7D(X62B`!D$U$K$6#0(H14+#,`TL'-:3!M7,@
MWMQ!#0HF8AG.UQ,KWOE>]:BN[$_6^CN>R]_J%?\`WE6N/N4COY8J83'#G[(P
M?/3VFKPT(TFJ/=2=UIU1M<MWCDC!;($L&["3@6R+GT_#-/1%342!I"+D7$1!
M.A`$PPVP2PY(8Q?E0K_DBR>JQTG*K0NC,D1=L'I+KTOPYIMLNYPH:WZD[&&)
MK-.H/5J*45[SQ#;J3F5$0K@B"8W3=)C,JXL$]%YZAEQ<P!S660H'#8/.+?6;
ME!Y%<?\`IK#Q#9)JM5$0Y.C';CQ+-*EN*X=Q4!8QC9W3\WAU^`X]B6QH-./9
M1$FSM&K3,$\ARB9S0=RFA,BA>]N+B7KCM2TVE,,.*--T(-\.19R45ME^'$L3
M=M0E.$_8X80'(A3=%4:(<2YIIPZ6#,&U1+E.=).SX@G%YODBVSQROPXVLTDS
M<3/+TSU6"@4"@4"@4&%R04?)^.WZ0C!41T22CK+=)2/%IPAY"H"0^3*&>!:2
MHN!8)ROD*CD%_,N*9QL4-7R!PRMR(G_,R#03["?]3!WT=`^BJK\IU3+?^'$I
M>@V(/'.0I%+*>W6R^H\EZ]@M*307ZR(H;BD7D!>&/1D\"#-";HN>O+(QY4H_
M3*69,8^5"U\R@(N-N5O>P(C*3]>T3;PBQ_IIN`6?C),F=4]DRY<N[FV.../!
MDGA`@`A+)(048841KXX!A!X8WRRRRO:UK6X;U'69CE_24WQ9?B%/1I,(KX>T
MN0C$CR).-2'D-1FY-,J24KMD1,Q#2R2'@6C&3<@E`!5X1!+W`*VN'_\`*9?\
MVM.,5W:^XWA3_43D)$81Z3]O=&UN-"3T:QN0T5O-E3"7U=C%EPB,[4M#%SU>
M2,`E@^@8&`BV5S96V(V>-[C!_P#/QF5_PXE<CQCO_P#,'='_`/9I3_\`S='I
M/0]?]H:WM;HAUV<OB(&(W-1AX=4EP_+>GCN"7HLTU;C+<T(IRW&4Q1FY$IX;
M)1D;1%1HJ3L-FUKFS+6+<B8*6`4@;@#7$P'+NZS/^/=$SGU^BZ//#)39/@F"
MX#9\_'_$44F(WGT%'+;:J@J)[?\`%U<*4PF,\'@T4(L\18U2<F<A%+D`ALPR
MJ>EEL"X5N;%\<!><SBO_`$V5>&``22'IM,UIZ#-GO$709$$OL\]7(-@<,R)'
MRF>4C4$N^&!KDR(*1K@99M@RZ,B$@@L$12+FRYS#(W^?'1_RGMVKHV_562@4
M"@4"@U*;M1CXQ[OF0JJZ'[$ZM1;"6++1"AMLS&B'E!VB/D$^M9KRH$.7@N1@
M[(YI/%(X`X^4,;VS"$_,X</&SF6H^O>%K=)6MNBT(;-)6]\D11*4W9/1;-E'
M-#A$=/:(;&&((N""EB`&&%'(EU@JH`GLQLO)^5KX"A_GL^#BX5)KMT>2#_4@
MRKM#-6U:9K>PFI,3B@J$$9G.G!+0(K<=T`S,CA03:B?<A%S)J#F.Z,$MH.`F
M4+"V,9@$C`QX,*ULLA;Y9ET]*B+[O17X*,];.;%Z5%GWMHHK:E*J=)KK9X0K
MD89Q@+V#5;J*TPD2RL1,MIM@+IXT*8,&1%,O8V&8R'X@ACG`0X(-ACVB(G#[
M[M1CXQ[OF0JJZ'[$ZM1;"6++1"AMLS&B'E!VB/D$^M9KRH$.7@N1@[(YI/%(
MX`X^4,;VS"$_,X</&S9(^O>%K=)6MNBT(;-)6]\D11*4W9/1;-E'-#A$=/:(
M;&&((N""EB`&&%'(EU@JH`GLQLO)^5KX"A_GL^#BX5)KMT0#XML=),P:LLZ)
M5X^L)2%*.W>E$=+2HWCETY?34E[;1Q:VE$^AJ%L!+D%@F34\Q"PW%RY(;''+
M@OP<%)/7$M*FP<ER4]K[B15LF01,YPUUU'UFA27W`[DW(M&LK%4[>QNK32F6
MUS)4NGF6++,>KA!450,<;8D#8I\GGAC8"UKQKB8Z(^G(JT&AEX@K9C<MJ$`R
MGAJ3JXY\4SP_S1<C`3:569N0UD:^<M-A+!&00)N>(3QSNE'2HQ>XK?11\1"W
M'M<<0O:.O5[**KF4"@4%:-8?]R3%_:7G[_\`D%4HL]EEZ(4"@4"@4"@4"@4"
M@4"@4"@__]/W\4"@4"@4"@4"@4"@4&FW7SM$>QMB>;?;[\@>3#/D?V>?A;^8
MOD[RJ?YKYI>UC_VF>0.2X.:^7OY4Y+@YQ^<XU1J:M,OZT?[2W]SK53!^M'^T
MM_<ZT,'ZT?[2W]SK0P?K1_M+?W.M#!^M'^TM_<ZT,'ZT?[2W]SK0P?K1_M+?
MW.M#!^M'^TM_<ZT,,`6.U'[26-_3O_FR_P#_`'Q^#K[2?]K9'\QO^[/_`&__
M`.E\FT,.$J=J/VLM#^G%_,UX?[T_!U]K/^\FS_-#_N;_`-L?]9YE0PB<_P!J
M/R0]?Z17](I&_P!O_!U\D?[4SOYZ_P#]BO\`ZE_Z7R?47"4DSM1^V%U?TW/Y
MC-?_`'9^#K[8?]ZKO\ZO^XW_`&7_`-;YU0Q24OUH_P!I;^YUJI@_6C_:6_N=
M:&#]:/\`:6_N=:&#]:/]I;^YUH8/UH_VEO[G6A@_6C_:6_N=:&#]:/\`:6_N
M=:&#]:/]I;^YUH8/UH_VEO[G6A@_6C_:6_N=:&#]:/\`:6_N=:&#]:/]I;^Y
MUH8/UH_VEO[G6AA&<Q]J/V8/3^G%_N87],?X.OLP_P#.@_ST_P"#?]+_`./Q
M:&$`ZF=J/_UV_3)_^!_T3/P=?^)_SV_^X_\`TU19IGYKM1^R]._I1_I8S_VK
M\'7V7_IF/_[N_P#%C_I?]\^5H899CVH_;V+_`$S_`-$)?_F_@Z^WO^>9G_SO
M_A#_`/-_\9X]#%)?_6C_`&EO[G6JF#]:/]I;^YUH8/UH_P!I;^YUH8/UH_VE
MO[G6A@_6C_:6_N=:&#]:/]I;^YUH8/UH_P!I;^YUH8/UH_VEO[G6A@_6C_:6
M_N=:&#]:/]I;^YUH8/UH_P!I;^YUH8/UH_VEO[G6AA@$B]J/R6@?T[_Y_P`>
M_I%_!U\E_P`\4;_<'_?_`-'O^,\WH80I,W:C\H2;_2$_1:T_TS?@Z^4/Y[G/
MTF_^%O\`V3_QOE*BXPBV,>U'[&)._GE_OEM_HQ_!U]C'^WIOZ3O^,_\`9O\`
MUCD:&+7\_6C_`&EO[G6JF#]:/]I;^YUH8/UH_P!I;^YUH8/UH_VEO[G6AA,&
MC/EWV3O?SG\]?.'M`SWY8]I'LY\_>>>TI<X?.OV0_P#LO\K<EQ>'R'_$>3XG
;!^<Y2A/9<VB%`H%`H%`H%`H%`H%`H%`H/__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
